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Abstract
Despite recent improvements in the ability to prevent osteoporotic fracture a vast
number ofmainly elderly patients continue to sustain fractures resulting in
significant morbidity and a huge demand on health care services. Current knowledge
of the process of fracture healing in osteoporotic bone is limited but there is a
suggestion that it may differ from that of normal bone. An improved knowledge of
the mechanical and biological properties of healing fractures in osteoporosis could
ultimately lead to an enhancement of our ability to treat this problem by both medical
and surgical means.
The aim of this study was firstly to use an animal model to investigate the
histological and mechanical properties of fracture healing in osteopenic bone.
Secondly, the same model and outcome parameters were used to study the effect on
fracture healing of the systemic administration of simvastatin, which recent studies
have suggested, promotes both bone formation and inhibits bone resorption.
In part one of the study 20, 3-month-old female, Wistar rats underwent ovariectomy
(Ovx) while a further 20 had a sham procedure to act as controls. Seven weeks later a
transverse fracture was created in the proximal tibia of each animal by three-point
bending with the resulting fractures supported by an intramedullary wire. Half of the
animals in each group were euthanased at two weeks and the remainder at four
weeks post fracture with the tibiae removed post mortem. All tibiae were then x-
rayed. The mechanical properties of half of the healing fractures were ascertained by
four-point bending to failure while the remaining specimens were prepared for
histological analysis and immunohistochemistry. There were no mechanical
differences in the fracture calluses from the ovx animals compared with control at
two weeks but by four weeks post fracture the ultimate load at failure of the fractures
from the ovx animals was reduced to 71% of that from controls. Stiffness (54%) and
stress at yield (74%) were also reduced while the strain at yield was increased by
40% in fractures from the ovx group. Histological differences were also seen with an
increased porosity of the calluses from the ovx group at four weeks. No radiological
differences were note and there was no difference in the expression of the key
growth factors BMP 2, BMP 6 or Smadl. No difference in the replication of key cell
populations was seen.
In the second part of the study the same animal model was used with the groups once
again divided into ovx and sham controls. Half of each group received placebo while
the other half received simvastatin 20mg/kg daily for 14 days post fracture. The same
time points and outcome measures were used as in the first part of the study. In the
sham groups simvastatin had no detectable effect on the radiological or mechanical
features of the fractures or on the expression of the growth factors studied. The only
difference was a higher proportion of immature bone in the four-week-old calluses
from the simvastatin group (40%) versus placebo (34%). In the ovx animals
simvastatin had a more noticeable effect with, once again, a higher proportion of
immature bone in the four week old calluses in the drug group (43%) versus 28% in
the placebo group. In addition the four-week-old healing fractures in the statin group
had smaller calluses (16mm2 compared with 28mm2) and were able to withstand only
76% of the ultimate load before failure than the fractures from the placebo fed ovx
controls. An increased level of Smadl expression was also seen in the chondrocytes
of the statin fed ovx group.
The findings from the first part of this study provide evidence that an osteopenic
environment has a deleterious effect on the mechanical properties of healing
fractures in the rat model with an associated impairment of callus maturation.
Contrary to previous work the dose and method of delivery of simvastatin in the
second part of this study had no apparent effect on the fracture healing in normal
bone. However simvastatin appeared to have a deleterious effect on fracture healing
in the osteopenic model causing a reduction in callus size and maturity and reducing
the healing fractures' ability to withstand load. This study does not support a role for
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The World Health Organisation (WHO) has defined osteoporosis in two ways. Firstly, as
a ''progressive systemic disease characterized by low bone mineral density (BMD) and
micro-architectural deterioration of bone tissue, with a consequent increase in bone
fragility and susceptibility to fracture". Secondly, and more precisely, as a BMD ofmore
than 2.5 standard deviations below the young adult mean '. Commonly the BMD is
expressed relative to the young adult reference as a T-score.
1.1.2 Epidemiology
Using the second of the two WHO definitions it is estimated that as many as 30% of
postmenopausal women will suffer from osteoporosis. Up to 70% of all hip fractures can
be attributable to osteoporosis with population demographics predicting an exponential
rise in hip fracture incidence until the middle of this century 2. In 2001 over 180000
osteoporosis related fractures occurred in the United Kingdom resulting in an estimated
cost of £1.7 billion 3.
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Introduction
Currently, the true incidence of osteoporosis in populations can only be inferred from
fracture incidence, as osteoporosis sufferers who do not fracture do not usually present
to health care services. There is substantial variability in the incidence of osteoporotic
fracture with Caucasian women in Northern Europe having one of the highest incidences
in the world. The accelerated bone loss post menopause together with the fact that
women live longer than men make the life time risk for women of an osteoporotic
fracture almost three times that ofmen in the USA 4. While osteoporosis has a major
association with hip fracture 5 it is not the only factor with environment and other co¬
morbidities influencing fracture incidence 6. Inferences about osteoporosis incidence
from fracture rates should therefore be made cautiously.
1.1.3 Pathogenesis
The continuous remodelling of bone throughout life maintains a healthy skeleton
capable of withstanding and adapting to load. With the onset of osteoporosis the balance
of bone formation and resorption fails with a net resorption resulting. Resorption on the
endocortical and trabecular surfaces results in cortical and trabecular thinning with
eventual loss of trabeculae and increased cortical porosity.
Toss of bone begins soon after peak bone mass has been achieved and is therefore not
entirely due to gonadal failure 7 but may also be due to falling osteoblast numbers
associated with aging 8 . Oestrogen deficiency is however a major factor in causing the
accelerated bone loss in women seen following the menopause 9. After the initial rapid
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loss of BMD a steady state is reached where remodelling remains negatively balanced
with increased numbers of remodelling sites on trabecular bone. At these remodelling
sites osteoclasts predominate due to the increased osteoclastogenesis and a reduced
osteoblast lifespan 10 associated with oestrogen withdrawal.
A direct role for oestrogen on osteoblast and osteoclast activity was suggested by the
identification of oestrogen receptors (ER) on both cell types n'12. The exact response of
these cells to oestrogen has not been defined but in vitro work has shown osteoblasts
responding to oestrogen exposure by production of procollagen and expression of
1
growth factors as well as reduced expression of osteoclastogenic cytokines
interleukins (IL)-l, 6 and tumour necrosis factor 1 '15. Oestrogen has also been shown to
promote mesenchymal stem cell differentiation into osteoblastic lineage 16 and promote
bone morphogenic protein (BMP)-2 and transforming growth factor (TGF)-B production
in osteoprogenitor cells 17.
There is a clear link between oestrogen and growth factors known to promote bone
formation with an apparent cross-talk between BMP and oestrogen signalling pathways
18. Matched temporal expression ofBMP-2 and 4 and their intracellular signalling
protein, Smad-4 with ER expression has been reported 19'20. BMP-4 signal transduction
is influenced by oestrogen21 and a paracrine role for BMPs in the regulation of ovarian
99 •
response to the oestrous cycle has been proposed . While there is abundant evidence of
a link between oestrogen and growth factor regulation, the purpose of this and its role in




factors such as BMPs 2, 4 and 6 would seem to be an obvious mechanism for the
osteogenic action of oestrogen24 but this hypothesis is hindered by the knowledge that
anti-oestrogens can have similar effects on these growth factors 25.
The osteocyte is known to have an important role in the regulation of bone structure in
response to load26. Oestrogen withdrawal has been shown to result in increased
osteocyte apoptosis both in vitro 27 and in vivo 28 in cortical and cancellous bone. The
loss of osteocytes in response to oestrogen withdrawal may result in a decreased
capacity for bone to remodel appropriately in response to load leading to the
microfracturing seen in osteoporosis.
Systemic factors such as parathyroid hormone (PTH) and vitamin D influence
• • • 29 • • 1 •
osteoclastogenesis via cells of osteoblastic lineage . This influence is exerted via an
osteoclast differentiation factor known as RANK ligand (RANKL) which is a common
factor in osteoclast promotion by any stimulus 30. Blockage ofRANKL results in
osteopetrosis due to failure of osteoclast formation and over expression ofRANKL has
been shown on trabecular bone from osteoporotic women 3l. The direct role for
oestrogen in preventing osteoclastogenesis is seen by the down regulation ofRANKL
with oestrogen supplementation 32.
A genetic predisposition to osteoporosis has long been suspected. Known genetic factors
such as age at menarche and menopause and body mass have an influence but more
specific genetic features are being identified. Polymorphisms and mutations of genes
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ranging from those for ER, collagen type one, IL-6 and TGF-B have all been shown to
increase the risk for osteoporosis 33'34. This would support the hypotheses that these
factors all have a key role in the pathogenesis on osteoporosis.
The development of osteoporosis involves the disturbance of the complex regulatory
factors governing the balance of bone remodelling. An increased knowledge of the
mechanisms involved has facilitated the introduction of treatments aimed at maintaining
and possibly even restoring bone mass in late adult life.
1.1.4 Treatment of osteoporosis
Osteoporosis is a multi-factorial disease with alterations in life style such as cessation of
smoking and increased exercise known to be beneficial. However, therapies aimed at
preservation of bone mass constitute the mainstay of current pharmacological
treatments.
Calcium and vitamin D
Various studies have shown a reduction in the risk of fracture when elderly individuals
who are calcium or vitamin D deficient receive supplementation 35'36. There appears to
be no benefit however to those with a normal nutritional status 37'38. This suggests that
this treatment is effective in treating co-existing osteomalacia but is not in itself an
effective treatment for osteoporosis.
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Oestrogen therapy and oestrogen analogues
Hormone replacement therapy (HRT) appears to be effective at inhibiting bone loss
following the menopause 39 but following its cessation bone loss resumes at the post
menopausal rate 40. The evidence that HRT reduces the risk of fracture is limited. No
large trials have been conducted to look at fracture specifically but meta-analyses of
available data suggest a reduction in vertebral and non-vertebral fracture by 25 to 33%
41. Unfortunately withdrawal ofHRT results in loss of the reduced fracture risk in a
relatively short period 42 indicating that a delay in bone loss is all that is achieved while
receiving HRT. The major disadvantage of prolonged HRT is the associated increase in
breast cancer. The incidence of breast cancer is increased by HRT treatment ofmore
than 5 years although mortality from the cancer is not clearly affected 43. Long term
oestrogen treatment for osteoporosis is therefore no longer a viable option.
The selective oestrogen receptor modulator (SERM) raloxifene acts as a competitive
inhibitor of oestrogen in the breast but conversely as an oestrogen agonist in bone. A
pro-osteoblastic and anti-osteoclastic action of raloxifene has been demonstrated in vitro
44. The MORE study (Multiple Outcomes ofRaloxifene) showed that raloxifene
treatment reduced the incidence of breast cancer but also reduced the incidence of
vertebral fracture in osteoporotic individuals 45. Unfortunately no reduction in non-




These pyrophosphate analogues have a strong affinity for bone apatite. This results in
inhibition of osteoclast function and reduction in osteoclast number translating into an
inhibition of bone resorption46 and of bone loss following gonadal failure 47. It has been
proposed that one of the mechanisms of action is by inhibition of enzymes in the latter
• • 48
part of the mevalonate pathway which results in osteoclast apoptosis . Some concern
does exist however over the long-term consequences of the inhibition of bone turnover
and remodelling caused by bisphosphonates. Bourrin et al. 49 reported no restoration of
bone architecture following bisphosphonate therapy but the long-term sequelae of this
are not clear.
Large clinical trials have shown prolonged treatment with the bisphosphonates
alendronate and risedronate reduces the incidence of fracture by up to 50% with the
protective effect occurring within 12 months of commencing treatment50"52. Evidence
for a prolonged benefit or even absence of a deleterious effect after five years of
treatment is however still lacking.
Parathyroid hormone (PTH)
PTH appears to be a truly anabolic agent when delivered appropriately. Increased bone
mass has been seen in animal models after intermittent injection with anabolic effects on
cortical and trabecular bone 53°5. An initial increase in cortical porosity is seen due to




Human trials using synthetic human PTH (1-34) have all shown an increase in BMD 56"
58. This appears to translate into a reduction in fracture risk with Neer et al. 59 reporting a
relative risk for vertebral fracture of 0.35 for PTH versus placebo treated women. The
anabolic nature ofPTH raises some concerns about possible oncogenesis with very large
long-term doses ofPTH resulting in the majority of animals in one study developing
osteosarcoma60. No oncogenesis has been reported with lower, more physiological
doses used over the shorter term. Another disadvantage of PTH is the current necessity
for it to be delivered by injection although oral preparations are being attempted.
Statins
This class of drugs is one of the most widely used in western society due to its
cholesterol lowering properties. They act by inhibition of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase which catalyses a fundamental step in the hepatic
synthesis of cholesterol via the mevalonate pathway (see Figure 1). Statins are described
as pleiotropic due to a variety of differing effects on various physiological systems not
all of which can be ascribed to the cholesterol lowering effect. An apparent cerebral
sparing effect in cerebral ischaemia has been associated with endothelial nitric oxide
enhancement resulting from reduced geranylgeranylated proteins which are an end
product of the mevalonate pathway (see Figure 1) 61. The extent of the pleiotropic effects
appears to be due to the inhibition of formation of the non-steroidal isoprenoids which
have multiple roles in cell function, signalling and replication 62. The anti-
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atheromatous effect of statins is due not only to the lipid lowering function but also the
effect on endothelial nitric oxide and an anti-proliferative effect on arterial myocytes 64.
Mundy et al. 63 first observed an apparent promotion of bone formation in a rat model
after statin administration topically and systemically in normal and osteopenic animals.
This finding was supported by well designed in vitro work which showed an increase in
BMP-2 expression in osteoblastic cells which was thought to be the cause of the statins
osteogenic effect. The bone forming effect of statins was inhibited by addition of the
BMP-2 inhibitor, noggin, which supported this hypothesis. A dose dependent increase in
BMP-2 production was also demonstrated by Sugiyama et al. in human osteosarcoma
cells in vitro 66. Several other studies have produced in vitro evidence of osteoblast
stimulation and increased BMP-2 levels as well as an apparent anti-osteoclastic effect of
statin administration 67"69. Prolonged administration of simvastatin has been shown to
result in increased cancellous bone formation in one year old rats 70 but additional work
has suggested that an initiation of the osteogenic cascade occurs after only limited
administration of statins to culture and animal models 71.
Contradictory results have however been reported. Maritz et al. 72 in a well constructed
study, found that prolonged treatment of rats with three different statins at the same
doses used by Mundy et al. resulted in no change in bone mineral density. A stimulation
of both bone formation and resorption occurred with a simvastatin dose of 20mg/kg




causing BMD to fall. Banu and Kalu have more recently reported no beneficial effect
on lumbar BMD in the rat after prolonged treatment with cerivastatin. Similarly Staal et
al. 74 reported finding no increase in bone formation following cerivastatin treatment in a
parathyroidectomy rat model but they did see an anti-resorpative effect of the drug in
vitro.
The different results reported may be due to differing methods. The type of statin used is
important as the earlier less lipophilic statins penetrate bone poorly but this would not
explain the contradictory results with cerivastatin which is highly lipophilic. The dose
related effects shown by Maritz et al. 72 may also be important. Differing doses, methods
of delivery and types of animal model make comparison betweens studies difficult.
Another key difference between the methods of Mundy et al.65 and Maritz et al. was the
timing of statin administration in relation to ovariectomy. Maritz et al. administered the
drug only two weeks post ovariectomy during which time it is known that dramatic
resorptive activity is occurring 75 while Mundy et al. waited until two months post
ovariectomy. While both studies were adequately controlled suggesting the drug effects
seen were genuine it may be that the simvastatin effect depends upon underlying bone
resorptivc activity. Comparison between species is always dangerous but it is known that
rats react to HMG-CoA inhibition by increasing HMG-CoA production which is not the
initial response to statins in humans 76. Comparing effective doses between species and
from in vitro work is therefore extremely difficult.
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There is some evidence for statins having an effect on bone in humans. An effect on
markers of bone resorption has been seen in human trials of simvastatin and cerivastatin
77'78. Whether this translates into a beneficial effect on bone mineral density in humans is
debatable. Observational and case controlled studies report contradictory findings. The
case-controlled Chingford study 79 appeared to show a clear increase in BMD in women
taking a statin for cardiovascular reasons but other population based studies failed to
find any difference in BMD in similar groups " . These findings have been based on
analysis of secondary outcomes from other study groups and no data is available from a
large, randomized controlled trial comparing the effect on human BMD of statin versus
placebo.
The same is true for the evidence of a statin effect on fracture risk. Data from several
retrospective, case controlled studies in large populations do appear to suggest a
reduction in fracture risk associated with taking statins. Meier et al. 83 reported that data
retrieved retrospectively from the general practice research database in the United
Kingdom showed an odds ratio of fracture of 0.55 with statin use. A number of other
similar analyses of population databases report equivalent reductions in fracture risk
with statin use '5. However, the same database used by Meier et al. was analyzed in a
different way by van Staa et al. who found no difference on the odds ratio for fracture in
statin or non-statin users 86. This demonstrates the difficulty of drawing conclusions
from retrospective data and post-hoc analyses of other studies. Multiple confounding
factors such as social class, smoking, body mass or exercise are very difficult to control
for and may significantly affect the results. The question of whether statins affect BMD
12
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or fracture risk currently remains unanswered but the evidence that does exist justifies an
attempt to address this question.
1.2 Fracture healing
Re-establishment of osseous integrity following fracture involves a complex cascade of
cellular responses governed by autocrine, paracrine and endocrine mechanisms. These
governing mechanisms are themselves influenced by the mechanical and physiological
environment in which the fracture is trying to heal. This complex and incompletely
understood process, results in the restoration of the ability of the bone to withstand load
by regeneration of tissue rather than by scar tissue formation. This feature differentiates
fracture healing from other types of tissue repair following injury.
1.2.1 Types of fracture healing
Primary cortical healing
This process is defined as an attempt to restore cortical integrity by direct healing of
anatomically opposed, rigidly fixed fracture ends 87. Under such conditions ofminimal
interfragmentary strain, the Haversian system is reconstituted by remodelling units
known as "cutting cones". These units are comprised of osteoclasts which tunnel
through cortical bone allowing penetration by mesenchymal cells accompanied by
13
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revascularisation. The mesenchymal cells become the osteoprogenitor cells for the
osteoblasts. The cutting cones are able to cross not only areas of dead cortical bone but
oo
also small gaps at the fracture site . The process is however slow and is intolerant of
minimal mobility. It is analogous to the process of bone remodelling which occurs
throughout life.
Healing of cancellous bone
Cancellous bone benefits from a rich blood supply meaning that bone turnover can occur
on the surface of the trabeculae. This process is known as "creeping substitution" 87.
Additionally, the ample vascularity is given as one reason why there is minimal bone
necrosis at a cancellous fracture site. Charnley and Baker 89 demonstrated that
cancellous bone heals rapidly at points of contact between fracture ends under
compression and hypothesised that this was due to the persistent viability of the bone
ends. This is to be contrasted with cortical bone which would heal in similar
circumstances by the much slower process of primary cortical healing. In common with
compressed, immobilised cortical bone however, cancellous bone does not heal by
creeping substitution where direct contact does not exist.
1.2.2 Stages of fracture healing
Haematoma and inflammation
Common to all ultimate types of fracture healing is the initial creation of a haematoma
from the damaged bone and soft tissue. This haematoma plays an important role in the
14
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initiation of fracture healing as it appears to be a source of signalling molecules which
stimulate the healing cascade 90. Inflammatory cells release chemotactic cytokines
including interleukin (IL) -1 and IL-6 91. Platelets within the clot have been implicated
as the source of growth factors Transforming Growth Factor B (TGF-B) and Platelet
Derived Growth Factor (PDGF). These factors have an important role in the regulation
of cell proliferation and differentiation of stem cells 90.
Another early response is that of increased blood flow in the affected bone due to
increases in both endosteal and periosteal blood flow and a hyperdynamic response in
the entire region 92. It is hypothesised that this is regulated by local and systemic pro-
angiogenic substances such as vascular endothelial growth factor (VEGF) and
endothelial cell growth factor (ECGF) 93'94. The increased vascularity is associated with
invasion of the haematoma by fibrovascular tissue which promotes the laying down of a
collagen network.
Following this, healing can proceed in different ways. The process of primary healing
has already been described above. As mentioned this relies upon rigid stability and
contact which is not a common circumstance under which fracture healing takes place in
nature. More commonly varying degrees of instability and incongruence of the fracture
fragments exists. These conditions lead to production of callus and the more commonly
encountered process of secondary fracture healing.




External (bridging) callus, is produced rapidly from both fracture ends in an attempt to
bridge not only the fracture gap but also the dead bone at the end of the fragments and
confer a degree of early stability 95. An initial, time limited, reaction termed the "primary
callus response" begins rapidly after the fracture occurs. Intramembranous ossification
by osteoprogenitor cells in the cambial layer of the periosteum takes place a few
millimetres from the fracture ends 87. This results in advancing collars of callus from the
bone ends with the apparent objective of establishing cellular contact96. The area of
callus where intramembranous ossification occurs is termed the "hard callus". This term
is also applied to the callus formed in the latter stages of endochondral ossification.
Intense cellular proliferation occurs early and is relatively short lived in the hard callus
formed by intramembranous ossification, occurring maximally between days three and
seven following fracture 97.
An additional source of osteogenesis and regulation of the development of external
callus is thought to be the surrounding soft tissue. Rhinelander 92 demonstrated that the
healing fracture derives a significant extraosseous blood supply from the surrounding
soft tissue and the possibility of osteogenic induction in unassociated soft tissue is well
established 98'99. The undifferentiated mesenchymal cells which infiltrate the organised
haematoma are therefore potentially derived from several sources including the
surrounding soft tissue, the invading endothelial cells 100 and the bone marrow 101.
16
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While external callus has a collar of bone from intramembranous ossification, bone is
also formed via endochondral ossification. It is proposed that areas of low oxygen
tension at the fracture site influence the undifferentiated mesenchymal cells in the callus
• 102 • •
to undergo chondrogenesis . Despite the attempts to establish a blood supply to the
callus the mechanical forces that exist at the incompletely immobilised fracture gap
result in poor perfusion and relatively low oxygen tension 103. The relatively avascular
cartilage provides the rapid contact and partial stability desired to promote vascular
ingrowth of the callus and osteogenesis. This part of the callus is known as the "soft
callus". Undifferentiated mesenchymal cells show marked proliferative activity in the
soft callus as early as three days post fracture with proliferation of chondrocytes
occurring from around day seven to 21 97. The synthesis of collagen type-2 which
predominates in cartilage is maximal at the end of the first week and declines
dramatically by the end of week two. This has been shown to be the case in the healing
tibial fractures of three month old Wistar rats with the fractures supported with an
intramedullary wire 104.
Medullary callus forms at a slightly slower rate than the external callus. It appears to
derive its mesenchymal cells from the marrow elements of the fracture ends 105. It
appears to be less influenced by the mechanical environment as it has been seen to form
when the fracture is rigidly fixed 88 therefore facilitating primary bone union where
small gaps are present.
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The primary callus response is seen even where there is no hope of union such as in an
amputation stump 87. The example of the amputation stump however demonstrated that
if no contact with the other fragment has occurred with two weeks, the callus involutes.
This may also occur where non-osteogenic or necrotic tissue is interposed or excessive
movement prevents cellular contact and vascular bridging.
Cartilage calcification
Two weeks after fracture the rate of cell proliferation declines. Calcification of the
chondroid external and medullary callus then proceeds in a very similar way to that
which occurs at the physis. Hypertrophied chondrocytes release vesicles containing
proteolytic enzymes to degrade the matrix and release calcium to promote calcification
106
Cartilage removal and bone formation
The ingrowth of blood vessels is accompanied by a decline in the number of
chondrocytes and an increase in osteoblasts. The chondrocytes appear to undergo
07
apoptosis as part of an ordered transition to an osteoblastic environment . This leads to
the formation of immature, woven bone which replaces the cartilaginous callus over a




Restoration of lamellar structure occurs in response to load as defined by Wolffs law.
Osteoclast resorption ofwoven bone is followed by restoration of bone architecture into
lamellar and cancellous bone by the osteoblasts.
1.2.3 Regulation of fracture healing
Mechanical environment
The initial energy applied to create a fracture influences the ultimate healing process.
The greater the energy, the more the soft tissue and vascular disruption and the more
complex the fracture pattern. These factors have been shown to increase the incidence of
delayed and non-union l07.
As described above, the mechanical environment of the healing fracture exerts a
significant influence on the process of healing. At every stage from proliferation of
pluripotential tissue to remodelling of the healed fracture the mechanical environment is
• • 10^ • • • •
influential. Carter et al. in a theoretical analysis, hypothesised that intramembranous
ossification is permitted in areas of low to moderate stress and strain whereas increased
compressive stress and strain favour chondrogenesis. It has been shown that molecular
signals known to promote chondrogenesis are present very early in an unstable fracture
and persist for much longer than in a stabilised fracture 108. Excessive tensile strain has
19
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been shown to stimulate fibrocartilage. Claes et al. 109 showed that in a sheep model
strains of less than 5% promoted intramembranous ossification while those between 5-
15% promoted endochondrial ossification. Therefore, up to a point, the greater the strain
applied to a healing fracture the more abundant the external, endochondrial callus
formation. From the mechanical perspective this has an advantage as the larger the
diameter of the callus the greater its resistance to load due to its greater moment of
inertia.
The orientation of the fracture in relation to the applied load is also influential. In a well
conducted study using a rabbit model, Richards et al. 110 showed that increased shear
due to an oblique fracture under load resulted in decreased new bone volume.
Osteoblasts are known to respond directly to load and to orientate themselves
accordingly 109. As well as orientation, the extent of the fracture gap exerts an influence
over healing. Claes et al. 111 postulated that a larger gap size promoted callus formation.
In their ovine model however they found that a larger gap size of 6mm in a metatarsal
fracture impaired the mechanical properties of the healing fracture.
The timing of the applied load is also of importance. Where cyclical strain within limits
is applied early in the process healing appears to be enhanced. However if cyclical strain
• • • • • • • 112
is inappropriately applied at a later stage healing can be impaired . Therefore the
maintenance of optimal mechanical conditions throughout the healing process is
desirable but the optimal timing and nature of these conditions to promote rapid healing
is not yet established.
20
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Method of fracture stabilisation
The method of stabilisation chosen for treatment of an unstable fracture will clearly have
a profound effect on the process of healing. It has already been discussed how absolute
stability results in primary bone healing with production of some medullary callus.
"Absolute stability" would be achieved by a well reduced fracture being held by a
compression plate securely applied to the bone. Intramedullary nailing does not achieve
absolute stability 113. Stability is improved by contact and interdigitation of the fracture
fragments and by cortical contact with a large, reamed nail but bending moments still
exist which prevent primary bone healing. Rotational stability is entirely dependent on
the conformity of the reduced fracture fragments in the absence of interlocking of the
intramedullary nail. The other biomechanical feature of the intramedullary nail is that
even with interlocking, axial compression still exists at the fracture site 114. An
intramedullary nail therefore provides a stable reduction which permits secondary
fracture healing.
The effect of instrumentation and in particular reaming of the medullae of long bones
carried out during intramedullary nailing has been an area of concern. It has been
discussed that the medulla contributes mesenchymal cells and a blood supply to a
healing fracture and it would be reasonable to propose that disruption of this would
interfere with the healing process. This might be particularly important where the more
dominant extramedullary blood supply has been disrupted by the injury. Brinker et al. 115
showed that the endosteal nutrient artery is seriously disrupted by intramedullary
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reaming and does not recover for several weeks. Others have however found no
difference in healing following reaming, limited reaming or no reaming 116. Further
evidence suggests a faster time to union following reaming due to stimulation of the
extramedullary blood supply and delivery of''graft" to the fracture site even in open
fractures 117. The current evidence does not show a significant deleterious effect of
intramedullary instrumentation during fracture treatment.
Physiological factors
The general health of a person with a fracture has a bearing on fracture healing.
Anaemia 118, diabetes 119 and smoking 120 all impair healing.
• 121
A long bone fracture increases the metabolic requirement of the host by up to 25%
and many fracture patients are already malnourished. Vitamin D and C deficiency as
well as deficiencies of proteins such as albumin and transferring have all been linked
with delayed fracture healing 122.
Evidence for impaired healing with advancing age is limited. It is well recognized that
children's fractures heal faster then adults' which is thought to be related to the
increased vascularity and cellularity of children's periosteum. Additionally, animal
models have shown some impairment of fracture healing in older animals l23.
The maintenance of normal levels of growth hormone are beneficial to healing 124 but
the role of oestrogen and parathyroid hormone (PTH) are receiving increasing attention
as possible modifiers of the fracture healing process. Intermittent doses of PTH have
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been shown to increase bone formation via stimulation of osteoblast differentiation 125. It
has also been shown that PTH promotes callus formation and improves callus strength in
animal fracture models 126'127.
The potential role of oestrogen in fracture healing is discussed in the section on fracture
healing in osteoporosis.
1.2.4 Growth Factors and fracture healing
Marshall Urist 128 is credited with the discovery that extracts from demineralised bone
cause bone formation when transplanted into non-osseous connective tissue. He named
the responsible protein bone morphogenic protein (BMP) as, at that time, it was unclear
if one or more molecules were involved. Over the years since Urist's original work it has
become clear that multiple factors regulating bone growth exist of which BMPs are just
one group. Table 1.1 summarises the common growth factors involved with skeletal
regeneration. A clear understanding of the role of these growth factors has been sought
with the hope that better knowledge might lead to therapeutic manipulation of the
skeletal system in pathological conditions.
The role of the common growth factors in fracture healing will now be discussed.
Bone Morphogenic Proteins (BMPs)
The BMPs are part of a superfamily of growth factors termed the transforming growth
factor B (TGF-B) superfamily. Fifteen BMPs 129 have currently been identified largely
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through screening of human deoxyribosenucleic acid (DNA) libraries 130 following the
discovery of the genetic sequence of BMP by Wozney et al. 99. Not all BMPs are
osteoinductive with BMPs 2, 4, 6 and 7 (also known as osteogenic protein-1 (OP-1))
generally considered the most osteogenic. As well as osteogenesis, BMPs play a vital
part in the development ofmultiple tissue types with certain BMP deficiencies being
incompatible with successful embryogenesis 13°.
During the osteogenic process BMPs are secreted and act in an autocrine and paracrine
fashion. They bind to serine and threonine kinase receptor complexes classed into
BMPReceptor-lA and B and BMPRII, as is the case for most of the TGF-B superfamily
13 V Intracellular signaling is then accomplished via Smad proteins with this name
derived from their homologous nature to mothers against drosophila decapentaplegic
(MAD) protein. Eight Smads have been identified with Smads 1,4 and 5 known to enter
• • 1D
the nucleus after activation of the type 1 receptors . Phosphorylated Smads cross the
nuclear membrane resulting in direct or indirect cell activation. It is proposed that one of
the terminal mechanisms of action may be the production of osteoblast-specific factor 2
which may trigger differentiation of mesenchymal stem cells 133.
A role for BMPs in fracture healing is to be expected given the similarities between
fracture healing and embryogenesis. Yang and Jin 134 first identified BMP in
mesenchymal cells and osteoblasts at a healing fracture. Bostrom et al. 135 was able to
identify BMPs 2 and 4 in undifferentiated cells within the maturing fracture haematoma
and chondroid precursor cells during the second week following fracture. During the
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third week expression in the chondrocytes decreased and more marked expression was
seen in the osteoblasts. These findings were supported by Ishidou et al. 136 who also
investigated the expression of BMP 7 and the BMP receptors. They reported that BMP 7
was present in chondroid tissue early in healing but disappeared rapidly. BMPR IA and
IB up-regulation was seen by day 3 following fracture in osteogenic periosteal cells and
10R
by day 7 in fibroblasts, chondrocytes and osteoblasts. Le et al. showed the presence
of BMP 6 in hypertrophic chondrocytes declining prior to the end of the stage of
chondrogenesis suggesting a role for this BMP in regulation of the production of
cartilage. BMP 6 has however also been seen to promote osteoblast differentiation
directly in vitro in the early stage of osteogenesis 137.
Transforming Growth Factor-13. (TGF-B)
Five isoforms of this factor exist within the TGF-B superfamily. TGF-B1 is released by
platelets within the fracture haematoma and its presence has been identified in
proliferating periosteal cells in early healing 138. It is present in abundance during
endochondrial ossification with chondrocytes and osteoblasts expressing the receptor for
TGF-B at this stage 139. It has however been shown to be present at higher than normal
levels at the fracture site up to 28 days post fracture suggesting a role beyond that of
early healing '40.
Fibroblastic Growth Factor (FGF)
Different subtypes of FGF exist with the most common in adults being acidic FGF-1 and
basic FGF-2. FGF-1 has been shown to be mitogenic to chondrocytes with the more
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potent FGF-2 being expressed by osteoblasts 14The FGF receptors have increased
expression during fracture healing suggesting a role for these factors in this process l42.
Abnormalities of the FGF receptors have been implicated in abnormalities of
endochondrial and intramembranous ossification resulting in skeletal dysplasias
including achondroplasia l43.
Insulin-like Growth Factor (IGF)
IGF is released following secretion of growth hormone releasing hormone. IGF-1 may
have a role in promoting intramembranous ossification 144 but its precise involvement in
the fracture healing process has not yet been elucidated.
Platelet-derived Growth Factor (PDGF)
This factor is secreted by platelets which are involved in the formation of the fracture
haematoma. It has been identified at the fracture site in vivo and it is postulated that it
may play a role in the chemotaxis of different cell populations 145?146. Animal studies
have failed to show a clear beneficial effect on fracture healing from PDGF
supplementation l47.
Vascular Endothelial Growth Factor (VEGF)
Increased levels of VEGF have been found in the systemic circulation following trauma
and within the fracture haematoma 148. It is expressed in endothelial and osteoprogenitor
cells and osteoblasts at the fracture site with peak expression occurring within the first
26
Introduction
10 days following fracture 149'150. in an elegant study, Street et al. 151 demonstrated that
inhibition ofVEGF impaired both intramembranous and endochondrial ossification in a
murine model and VEGF supplementation dramatically enhanced the healing of
osteotomized rabbit radii. Its mechanism of action is incompletely understood but VEGF
is known to effect the expression and actions of BMP-2 and other members of the TGF-
B superfamily 152,153. As well as promoting angiogenesis at the fracture site VEGF
appears to directly upregulate proosteoblast and osteoblast activity 151'15 .
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Table 1 Summary of Growth Factors involved with skeletal regeneration 143
Growth Factor Source Function
Transforming Growth Factor
B(TGF-B)











































1.2.4.1 The use of Growth Factors in the enhancement of fracture healing
Increased awareness of the key role for growth factors in the process of fracture healing
has lead to the expanding field of growth factor manipulation in an attempt to enhance
fracture healing.
It has been known for many years that introduction of autologous bone graft at a fracture
site promotes osteoinduction as well as providing osteoconduction. This is contrary to
allogenic bone which provides only temporary osteoconduction 154. It has recently been
appreciated that the osteoinductive properties of autologous bone graft relate to the
presence of surviving osteogenic cells and osteoinductive growth factors 155. The donor
site morbidity associated with autologous graft has lead to a drive to deliver the
osteogenic cells and growth factors in improved ways. Osteogenic mesenchymal stem
cells have shown considerable promise when delivered to fracture sites in animals 156'157
but it has been recognized that this can be enhanced by the combined delivery of stem
cells with growth factors such as TGF-J3, FGF and BMP l58.
Delivery of growth factors alone has also been evaluated with the ability to produce
purified factors via recombinant DNA technology greatly enhancing this field.
BMP
Numerous animal studies using canine, rabbit and rat models, have demonstrated the
ability of BMPs 2 and 7 (OP-1) to promote healing of bony defects 159"161. Cook et al. 162
29
Introduction
has shown recombinant OP-1 (rhOP-1) to result in improved healing of bony defects in
primates when compared with autologous bone graft. Sciandini et al. 163 showed similar
effects of rhBMP-2 in a canine model. Rh- BMP has been shown to be effective in
producing spinal fusion 164 and several human trials have now been carried out using
BMP for the treatment of open tibial fractures, osteonecrosis and distraction
osteogenesis 165. RhOP-1 has now been shown to be as effective in achieving union in
human tibial non-unions as autologous bone graft166.
TGF-ft
Several animal studies have been conducted to evaluate the use of TGF-B in fracture
healing. The evidence to date is inconclusive with studies using regular high doses of
TGF-B showing enhanced bone formation and callus size 167'168 but others with different
doses or isotypes showing little effect 169. The pluripotential stimulus of TGF-B also
raises concern about its use in human trials.
FGF
Introduction of exogenous FGF into fracture sites in animal models does appear to
enhance fracture healing 170 . Improved mechanical properties and callus size have been
noted after treatment with rhFGF-2 in canine and primate models 171'172 but method of
delivery and dose again appeared influential.
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1.2.4.2 Methods of Growth Factor delivery and promotion
In many studies the method of presentation of the growth factors at the fracture site
proved critical. The ideal delivery vehicle needs to be biocompatible, biodegradable and
osteoconductive if critical defects are being bridged and the material must not act as an
impediment to bone healing as this would clearly be counterproductive. The majority of
clinical trials use absorbable collagen sponges (ACS) as the delivery vehicle with the
collagen often of bovine extraction. Other natural polymers such as hyaluronan, chitosan
and fibrin as well as synthetic polymers and ceramics have all been tried l73>174. Some of
these carriers allow percutaneous injection which is preferable in closed fractures.
The controlled presentation of the correct dose of factor has proved to be a major
limitation in this field of research. In studies, the higher the animal the greater the dose
of growth factor required. There is also an apparent need to maintain a high dose at the
fracture site for a prolonged period which again provides difficulties for the choice of
delivery vehicle 175.
The problems of direct delivery of non-physiological doses of growth factors have
encouraged research into other methods of manipulating growth factor presentation at
fractures sites. Promotion of growth factor expression by gene therapy techniques has
been investigated in numerous animal models. Direct injection of adenoviral vectors
containing BMP-2 has resulted in increased bone formation in rabbits and rats but only
to a limited extent in immunocompetent animals 176"179. The alternative, indirect
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technique has shown that several cells ofmesenchymal origin can promote bone
1 RO 1 R9
formation if injected with adenovirus transduced with BMP-2 or 7 . The advantage
of genetic manipulation of growth factor expression is that more physiological doses of
factor are expressed with a more appropriate temporal pattern. There is however concern
about inappropriate factor expression and unanticipated sequelae such as tumour
promotion as well as the currently prohibitive cost of gene therapy.
In 1999 Mundy et al. reported that statins appeared to stimulate bone formation both in
vitro and in vivo and proposed that this effect was via an increase in BMP 2 expression
65. From this work it was hoped that systemic administration of statin might prove
beneficial in conditions such as osteoporosis and further work in this area has been
carried out (see section on statins in: Treatment of osteoporosis 1.1.4). The implications
for manipulation of fracture healing have been less well investigated with only one study
to date having been published on this subject183. In this study it was reported that very
large dietary doses of simvastatin resulted in larger calluses and improved mechanical
properties of healing fractures compared with placebo in a murine model. The
mechanism of action was not investigated however and it is not known whether this was
related to an effect on growth factor expression. The possibility of enhancing fracture
repair by oral administration of an approved pharmacological agent is however of great
potential value and merits further work.
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Choice of animal model
A huge diversity of animals have been used in the study of fracture healing ranging from
birds, rodents, lower mammals and primates l84. Lower animals have the advantage of
reduced cost and abundant supply but the disadvantage of reduced applicability to
humans. Larger animals have the advantage of a wider choice of treatment modalities
but reduced availability reduces the power of much of the work. Mice and rats are
commonly used but care must be exercised as these animals do not reach skeletal
maturity and do not have well developed Haversian systems. Fracture healing in the rat
must therefore be classed as non-osteonal. The rat skeleton does however reach a steady
state following puberty at six weeks l85.
The rat long bone as a fracture model
Despite the disadvantages mentioned above, the rat is the most commonly used animal
for the study of fracture healing. Its increased size compared with mice allows easier
mechanical testing and offers a wider variety of treatment modalities for investigation.
An unsupported tibial fracture in the rat can be expected to have commenced
• 186endochondrial bone formation by ten days and bony union by 21 days
Creation of closed and open fractures of femora or tibia has been reported with
treatments ranging from no stabilization 187 to external fixation 188. The commonest form
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of fracture stabilization is intramedullary pinning. This is relatively easy to perform and
allows good mobilization and minimal interference by the animal post operatively. It
does however present the obvious disadvantages of potential introduction of infection
and disruption of the medullary component of fracture healing. The rigidity of the
intramedullary pin is also influential with non-union described when rigid pins have
been used l89. A pin diameter of no greater than 1mm is thought to be optimal 190.
Additionally, no rotational stability is provided by this method. Interdigitation of the
fracture with axial compression is the only provider of rotational stability and may be a
variable depending on fracture level and configuration. Similarly the level of the fracture
in relation to the pin will dictate bending forces with tibial fractures distal to the
tibiofibular junction poorly supported by an intramedullary pin due to the anatomy of the
rat tibia l90.
Creation of a standard long bone fracture in the rat has been achieved by various
methods. Creation of a closed fracture by digital three point bending or a guillotine
method has been described with the guillotine method having the advantage of
reproducibility 191. In most studies using the guillotine method of fracture creation the
femur or tibia is pre-supported by an intramedullary wire. This avoids the difficulty of
wire introduction into the fractured bone but increases the energy required to create the
fracture and possibly increases soft tissue damage. Despite this, this method,
standardized by Bonnarens and Einhorn l92, is currently the most widely used for the
study of closed mid-diaphyseal, long bone fractures.
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The alternative technique of osteotomy allows consistent fracture level and pattern but
changes the nature of the fracture model. Osteotomy results in more periosteal disruption
and slower healing than closed fracture 193 and comparison between results using the two
methods is difficult.
The ovariectomised (ovx) rat as a model of osteopenia
The ovx rat is a widely used as a model to study osteopenia. Ovariectomy results in a
rapid and definite increase in bone turnover with a predominance of osteoclast activity
194. Increased bone resorption can be detected as early as fourteen days post ovx with
increasing osteopenia up to 100 days later75. Li et al. 195 showed that by 30 days post
ovx the cancellous bone volume of the rat femoral neck was reduced to 75% of control.
The changes are mainly in the trabecular bone with cortical bone volume not changing
significantly until a considerable time later. It has been proposed that the loss of
trabecular bone volume is related to osteoclast perforation of trabecular plates which
occurs soon after ovx. Similarly, histomorphometry has shown ovx to induce endosteal
bone resorption but not influence periosteal bone formation 196.
As with all animal models caution has to be exercised in using this model and applying
the results to humans. The age at which the ovx is performed has been shown to be
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important with more pronounced changes occurring in younger animals . Ovx also
results in weight gain. This has caused concern with experiments designed to investigate
bone density or fracture healing due to the difficulties controlling for loading. Tibial
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bone volume has however been shown to be only minimally affected by uncontrolled
weight gain in this model 198.
The appropriateness of using sham operated animals as the control is also a concern.
Stress has been shown to inhibit the normal five day oestrous cycle in the rat as does any
enforced dieting or fasting 199"201. it is therefore important to ensure as low a stress
environment as possible for these animals and to ensure that sufficient time has passed
for the oestrous cycle to resume following sham surgery. Ensuring that a suitable
oestrous cycle has resumed can be carried out by serum oestrogen assay, vaginal or
uterine histology 198-202
Within these constraints, the ovx rat is considered a suitable model for the study of
osteopenia secondary to oestrogen depletion 203"205.
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1.2.6 Fracture healing in osteoporosis
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Despite the volume of research in osteoporosis there is a relative paucity of information
about the influence of osteoporosis on fracture healing. While prevention of fracture is
clearly a worthwhile aim the best currently available preventive treatments only reduce
the incidence of fracture by up to 50% in a high risk population 5 . This means that a
very large number of osteoporotic fractures will continue to occur for many years to
come. The osteoporotic fracture presents particular problems for treatment. Fixation is
difficult to achieve as screws can pull out due to their lack of hold in osteoporotic bone.
The resulting cutting-out of fixation devices limits the options for treatment. Ironically it
is this very group of patients where successful internal fixation would be most
beneficial. The elderly, osteoporotic patient benefits most from early mobilization with
loss of independence and significant co-morbidity associated with prolonged
immobilization. The ability to enhance fracture healing in osteoporosis and potentially to
speed up the process or improve the mechanical properties of the healing bone would
increase the treatment options for these patients. An improved understanding of the
process of fracture healing in osteoporosis is therefore desirable.
A role for oestrogen in fracture healing is suggested by evidence that oestrogen receptors
have increased expression in the fracture callus in the early stages of healing 206.
Additionally, cross talk between oestrogen receptors and BMPs integral to fracture
1 o
healing has been identified
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Initially it was unclear if any differences existed between osteoporotic and non-
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osteoporotic fracture healing. A limited study by Blythe and Buchsbaum appeared to
show no difference in the mechanical properties of healing fibular osteotomies in either
environment. More recently however, evidence has emerged to support the hypothesis
that important differences do exist. Bolander et al. 208 reported increased strength of
healing callus in the ovx rat following oestrogen injection. Hill et al. 209 showed the
mechanical properties of healing fractures to be poorer in the ovx group after 21 days
compared with a sham control. Very similar results were reported by Walsh et al. who
used healing femoral fractures supported by an intramedullary wire in the ovx rat as his
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model . Using a femoral osteotomy model in the ovx rat plus a low calcium diet,
Namkung-Matthai et al. 211 showed reduced callus formation and bone mineral density
at the healing osteotomy. This was associated with a three-fold reduction in resistance to
peak load in the ovx osteotomies compared with control at three weeks post osteotomy.
They concluded that this demonstrated a delay in callus formation in the ovx model.
919 •
This conclusion was supported by more recent work using a similar model which
showed increased soft callus in the ovx group compared with sham at four weeks post
fracture.
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Other workers have however reported contradictory results. Cao et al. reported that
calluses in ovx rats were larger than sham six and 16 weeks post femoral osteotomy with
histomorphological features consistent with more advanced healing. They found no
significant differences in the mechanical properties of the healing osteotomies in either
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group. Similarly, Kubo et al. 214 found no clear difference in the mechanical properties
of healing femoral osteotomies at six or 12 weeks after their creation in ovx versus a
non-fractured control (not sham operated). They did, however, see osteoporotic changes
in the new bone formed at the osteotomy site 12 weeks after osteotomy.
The method of each of the studies mentioned differed and may be an explanation for the
contradictory results. The age of animals, the time elapsed between ovx and fracture and
the use of closed fractures and osteotomies were different in each study. These factors
210
can all influence outcomes. The most comparable methods were between Walsh et al.
and Hill et al. 209 who reported similar results supporting the hypothesis that fracture
healing is impaired by ovx. The limited work in this field makes drawing conclusions
about the process of fracture healing in osteoporosis very difficult.




1 - To establish if mechanical differences exist between healing fractures of the
proximal tibia in an osteopenic rat model compared with a sham operated control
2- To investigate if histological differences exist between the healing fracture
calluses in the osteopenic rat model compared with control
3 - To investigate whether the expression of growth factors BMP-2, 6 and their
intracellular signalling peptide Smad-1 differ in osteopenic callus versus control
4 - To evaluate the potential influence of oral administration of simvastatin during
the early stage of fracture healing on each of the above factors
Hypothesis
That differences exist in the mechanical and histochemical properties of healing
fractures in an osteoporotic model versus control and that fracture healing can be








This research was covered by personal and project licences granted under the Animals
(Scientific Procedures) Act UK 1986.
2.1 Part 1
Fracture healing in the ovariectomy model versus control
2.1.1 Study design
Four month old female Wistar rats underwent ovariectomy (Ovx) or sham ovariectomy
(sham) through a standard dorsal approach under general anaesthesia. This was carried
out under license by the supplier Charles River (UK) prior to delivery. Opiate analgesia
was used post ovariectomy with no anti-inflammatory medication given at any time. The
animals were housed in groups of five and allowed to feed ad libitum until delivery to
our research facility seven weeks following ovx or sham surgery.
One week following delivery a tibial fracture was created in every animal by the method
described in Section 2.1.5.2. The animals were then divided into the following groups
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each containing ten rats housed in groups of five with the following post fracture
regimes:
Group A1 - Sham animals, received placebo, euthanased four weeks post fracture
Group A2 - Ovx animals, received placebo, euthanased four weeks post fracture
Group B1 - Sham animals, received placebo, euthanased two weeks post fracture
Group B2 - Ovx animals, received placebo, euthanased two weeks post fracture
Placebo was administered to the animals in order that this arm of the trial could act as a
control for part B of the study. Placebo (1ml vegetable oil) was administered by gavage
daily for two weeks following fracture. Animals were allowed to eat and drink ad
libitum throughout.
Following euthanasia the animals were weighed and the uterus and both tibiae removed
for analysis. Outcome measures were:
1 - Histological analysis of fracture site
2 - Radiological analysis of the fracture
3 - Immunohistochemical assay for expression of bone morphogenic proteins
(BMP) BMP-2 and 6, Smad 1 and bromodeoxyuridine (BRDU) as a marker of
mitosis
4 - Mechanical testing of the healing fractures
5 - Assessment of the efficacy of ovariectomy by;
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- Calculation of tibial bone mineral density of the intact, opposite tibia
- Body weight

















2.1.2 The fracture model
2.1.2.1 Environment and diet
Animals were housed in groups of five in standard cages with wood shaving bedding.
Temperature was maintained at 15 to 20 degrees Celsius with cycles of 12 hours of light
and dark every 24 hours. All procedures and husbandry were carried out during hours of
light. Animals were delivered one week before creation of fracture and handled daily to
allow acclimatisation to handlers and environment.
2.1.2.2 Age of animals
One of the limitations of the rat fracture model is that rats do not reach skeletal maturity.
Rapid growth however occurs in the first 6-8 weeks of life and by 5-6 months skeletal
growth rate has reached a plateau 215. Roholl et al. 216 showed that at six months skeletal
calcium flux had attained a steady state in female rats. An age of six months for creation
of fracture was therefore chosen.
2.1.2.3 Choice of time points for euthanasia
Animals were euthanascd by carbon dioxide inhalation. A two week time point was
desired to allow investigation of callus formation and expression of growth factors
which have been shown to be maximally expressed at this time 2I7.
By four weeks bony union has occurred in rat tibial fractures 186 and remodelling begins
218. This time point was chosen to investigate mechanical and histological features of the
fractures at bony union.
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2.1.2.4 Development and validation of the fracture technique
The technique for creation and stabilisation of a reliable transverse proximal tibial
fracture was developed and validated using the cadavers of 3-6 month old Wistar rats
kindly donated by the University of Edinburgh Small Animal Research Facility.
A method was sought to create a reliable, transverse fracture of the proximal tibial
metaphysis. The proximal metaphysis was chosen in order to provide a model of
cancellous bone healing. This was thought to be more relevant to the study of fracture
healing in osteopenia than the previously described mid-diaphyseal models. A cross
section of the tibia taken at the level of the fracture in our model (Figure 2.1.2) is
compared with a cross section from the mid-diaphysis of the tibia (Figure 2.1.3). These
figures demonstrate the difference in the proportions of cortical to cancellous bone at the
two levels. Intramedullary pinning also caused significantly less disturbance to the




Figure 2.1.2 Cross section of
proximal tibial metaphysis at the
intended level of fracture. The
passage created by the
intramedullary pin is highlighted.
(H&E x 25 light)
Figure 2.1.3 Cross section at the
mid-diaphysis of the same tibia as
figure 2.1. The disruption of the
intramedullary bone caused by the
intramedullary pin can be seen.
(H&E x 40 light)
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Reliability of the method was defined as creation of greater than or equal to 90%
acceptable fractures. Fractures displaying any spiral component or comminution or those
occurring out with the proximal third or involving the proximal physis of the tibia were
defined as unacceptable. The following methods of fracture creation were assessed.
Digital three-point bending with the fulcrum positioned laterally, medially, posteriorly
and anteriorly failed to create a reliable closed fracture of the proximal third of the tibia.
Significant force was required and resulted in comminution at the fracture site (Figure
2.1.4) and in one specimen, dislocation of the distal femoral physis (Figure 2.1.5). This
technique produced only 24/40 (60%) acceptable fractures.
Three-point bending with the three pressure points applied by polythene rods was also
attempted. While this resulted in a more reliable fracture configuration, problems were
encountered with securing the limb and preventing rotation during the fracture process
due to the curved shape of the rat tibia. This resulted in an inconsistent direction of
application of force and many fractures were occurring out with the proximal
metaphysis. Thirty-three out of 40 fractures (82.5%) were unacceptable. Once again, the
force required to fracture the metaphyseal bone resulted in an unacceptable degree of
soft tissue crush injury, ft was therefore decided to abandon attempts to create a closed
fracture.
An open technique was then assessed. The anterior crest of the proximal tibia was
exposed through a short, longitudinal incision. The same incision was used to allow
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passage of the intramedullary wire for fracture stabilisation (discussed below). A 2mm
notch was then made with bone cutters in the anterior crest of the tibia at the desired
level. Application of digital three-point bending with the fulcrum centred over the
medial side of the notch resulted in a reliable, transverse fracture with minimal soft
tissue crushing. This also resulted in reliable fracture or dislocation of the fibula. This
was important as it has been shown that the integrity of the fibula influences the
mechanical properties if the healing tibial fracture. This technique was repeated on 40
hind limbs of 20 rat cadavers resulting in 37 (92.5%) suitable fractures. This method of
fracture was therefore adopted (see Figure 2.1.6).
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Figure 2.1.4 Radiograph of severely comminuted tibial fracture created by
closed three-point bending
Figure 2.1.5 Radiograph of femoral physeal




Figure 2.1.6 Radiograph of 4 cadaver limbs with tibial fractures created by open
technique
Methods
2.1.2.4 In vivo fracture creation and stabilisation
Induction and maintenance of general anaesthesia
Anaesthesia was induced by gas inhalation of 5% halothane in air with supplemental
nitrous oxide. For maintenance, halothane was reduced to 1%. A satisfactory level of
anaesthesia was confirmed by loss of corneal reflex and withdrawal response.
Surgical preparation
The anterior aspect of the right lower limb was then shaved to expose the knee joint and
upper third of the lower leg. The exposed area was cleaned with methylated spirit and a
sterile drape applied leaving only the prepared surface of the knee and leg exposed. No
intravenous antibiotics were given.
Surgical technique
Aseptic technique and disposable instruments were used throughout with the exception
of a supply bone cutters which were sterilised in an autoclave between cases. A 5mm
longitudinal incision was made in the midline over the lower aspect of the patella tendon
and upper tibia. A 16-gauge hypodermic needle was then passed through the tendon and
used to create an entry point through the anterior aspect of the proximal tibial plateau
into the medullary canal of the tibia. A 0.8mm stainless steel wire was then passed down
the intramedullary canal until resistance was encountered indicating it had reached the
distal tibial diaphysis. The wire was then marked, withdrawn and cut to length.
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Manipulation of the skin allowed exposure of the proximal tibial crest through the same
incision. A pair of small bone cutters were used to create a 2mm notch in the anterior
crest of the tibia 5mm distal to the tibial tuberosity. A three-point bend was then applied
digitally to complete the tibial fracture. The fulcrum was placed over the medial aspect
of the tibia at the level of the notch.
The wire was then re-passed down the intramedullary canal and firmly engaged in the
distal tibial diaphysis. Care was taken to ensure the proximal aspect of the wire was not
prominent at the knee.
The surgical wound was then closed with a subcuticular 6/0 nylon suture supplemented
with acrylic glue to seal the wound. No wound dehiscence or clinically apparent
infection was observed with this technique.
Subcuticular buprenorphine was then given for analgesia and the halothane
discontinued. Non-steroidal anti-inflammatory analgesia was avoided due to its effects
on fracture healing. Animals were recovered in isolation and returned to preoperative
housing conditions on recovery. Full weight bearing through the affected limb was
observed within a few hours of surgery.
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Figure 2.1.8 Creation of the entry hole in the proximal tibial plateau with 16-
gauge needle
Figure 2.1.7 Vertical incision exposing patellar tendon with left knee flexed
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Figure 2.1.9 Insertion of pre-measured intra-medullary pin
Figure 2.1.10 Wound after closure with subcutaneous stitch and acrylic





The effect of simvastatin on fracture healing in normal and
osteopenic bone
This part of the study was run concurrently with Part 1. This allowed the placebo fed
animals in part 1 to act as controls for Part 2 of the study.
2.2.1 Study design
Four month old female Wistar rats underwent ovariectomy (Ovx) or sham ovariectomy
(sham) through a standard dorsal approach under general anaesthesia. This was carried
out under licence by the supplier Charles River (UK) seven weeks prior to delivery. The
animals were housed in groups of five and allowed to feed ad libitum following surgery.
One week following delivery to our research facility, a tibial fracture was created in
every animal by the method described in Section 2.1.2.4. The animals were then divided
into the following groups each containing ten rats housed in groups of five with the
following post fracture regimes (see Figure 2.2)
Group A3 - Sham animals, received simvastatin, euthanased four weeks post fracture
Group B3 - Sham animals, received simvastatin, euthanased two weeks post fracture
Group A4 - Ovx animals, received simvastatin, euthanased four weeks post fracture










































































2.2.1.1 Administration of simvastatin
Simvastatin was administered in the form of ZOCOR (Merck & Co, USA). See
Appendix A1.7 for full description ofZOCOR. This was finely ground and suspended in
vegetable oil on the morning of administration. Vegetable oil has been used previously
as a vehicle for oral delivery of statins 72 as they are insoluble in water. Measured doses
of statin were delivered by rigid tube gavage in the same way as delivery of placebo in
Part 1 of this study.
Administration of statin or placebo was carried out at 9am each morning for 14 days
starting on the day following creation of the tibial fracture.
Experimental conditions were otherwise identical to those in Part 1.
2.2.2.2 Dose of simvastatin
A dose of 20mg/kg was chosen on the basis of previous work carried out by Mundy et
al. 65 and Maritz et al12. Both investigators had shown effects on osteoporotic bone at
ioi
t #
this dose. The dose of 120mg/kg used by Skoglund et al. in their study on fracture
healing was considered too high with toxic effects demonstrated in mammals at
50mg/kg and above 76. The dose of 20mg/kg produces a serum level in the rat five times




As it was of primary interest to investigate the morphology of the healing fractures, it
was decided that samples should be fixed in formalin, decalcified and embedded in
paraffin to provide sections with optimum morphology. The possible effects of this
method of specimen preparation will now be discussed.
2.3.1 Fixation
The tibiae and fibulae from each animal were dissected out leaving a cuff of soft tissue
around the fracture site so as not to violate the callus. The samples were immediately
immersed in 4% formaldehyde in phosphate buffered saline at pH 7.2-7.4 and left for 48
hours. A period of 24 to 48 hours is accepted as sufficient for fixation ofmost tissues
after Helander 219 showed the quantity of fixed tissue plateaus after this period.
The process of formalin fixation involves development of protein cross-linking. While
this process has no effect on histological appearance of the specimen it has implications
for immunohistochemical techniques and will be discussed further in Sections 2.6 and
2.7.
2.3.2 Decalcification
To permit sectioning in paraffin, bone requires decalcification prior to mounting.
Removal of calcium and resulting dissolution of hydroxyapatite can be achieved by
strong acids or chelating agents. Acids such as nitric and hydrochloric have the
advantage of achieving rapid decalcification but at the cost of hydrolysis of nucleic acids
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and denaturizing enzymes 220. This can significantly hinder subsequent assays and
• 221immunohistochemical techniques . For this reason, specimens were decalcified in
disodium ethylenediamine tetraacetic acid (EDTA) at pH 7, which acts as a chelating
agent.
Complete decalcification was verified by x-ray analysis of specimens using a table-top
x-ray unit (Faxitron, USA). All samples were completely decalcified after 4 weeks at
37°C with weekly changes ofEDTA.
2.3.3 Processing
After complete decalcification and further trimming, the specimens were processed in an
automated processor to allow embedding in paraffin. The processing protocol is shown
in Appendix A1.1.
Following processing the specimens were mounted in paraffin blocks with great care
taken to orientate the specimens horizontally. This was to permit longitudinal cross
sections of the tibiae to be cut.
2.3.4 Sectioning
5pm sections were cut on a standard microtome (Shandon) and mounted on "Superfrost
plus" slides (BDH) after floating on deionised water at 40°C to remove ridges. Slides




Slides were then stored in a dry, dark environment at room temperature until use in
histological or immunohistochemical procedures.
2.3.5 Analysis of sections
In order to study the general morphology of the healing fractures three slides from each
specimen were stained with haematoxylin and eosin (H&E) and viewed under light
microscopy at magnifications from x25 to x400. See Appendix A1.2 for H&E method.
Five sections were taken 250 pm apart to control for variability through the specimen.
Formal quantification of tissue types present at the fracture site was performed using a
36-point graticule. The fracture site was defined as beginning where the periosteum
became elevated to where it returned to cortical contact beyond the fracture and all
tissue within this area was quantified using the graticule. Tissue types were recorded as:
Lamellar or trabecular bone
Woven bone
Cartilage
Marrow or trabecular space
Undifferentiated tissue
Each section was mapped twice at different times and a third time by an independent
observer to control for inter and intra-observer error (see Appendix 2).
Results were expressed as number of points for each tissue type at the fracture site over
the number of total points mapped and then expressed as a percentage. The results from




After fixation but prior to decalcification, all tibiae were x-rayed. Tibiae were placed in
a right lateral position after removal of the fibula to facilitate consistent positioning. All
samples were exposed at 50 KvP for 45 seconds with the image captured on Polaroid
film (Polaroid Inc, USA).
Negative images were analysed for presence of fracture line and scored as:
Fracture line complete = 1
>2/3 diameter = 2
1/3 to 2/3 diameter = 3
<1/3 diameter = 4
Fracture line absent = 5
The median, range and 95% confidence intervals for each group were then calculated.
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2.5 Immunohistochemistry for detection of Bone Morphogenic Proteins
(BMP) 2 & 6
2.5.1 Basis of technique
Immunolocalization of BMP in frozen and paraffin sections of rat tissue by indirect
techniques has been successfully demonstrated previously 222. The primary antibody to
BMP-2 used in the following technique was successfully used by Yu and co-workers 140
2.5.2 Specimen preparation
Sections prepared in the standard way, as described in Section 2.3, were dewaxed and
rehydrated to distilled water.
2.5.3 Effect of prolonged storage
To control for possible effects on the sections of storage at room temperature for an
average of eight weeks, a selection of fresh sections were cut and processed in the same
experimental run. As no difference in staining intensity between the fresh and stored
sections was demonstrated, the stored sections were accepted as representative.
2.5.4 Antigen retrieval
Most antigen retrieval is carried out using a combination of heat and pressure.
Unfortunately this led to unacceptable damage to sections and was abandoned as a
technique in this study.
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Antigen retrieval was performed with trypsin solution as described in Appendix A1.4.
Slides were immersed in trypsin solution at 37°C for 20 minutes. This time was derived
from trials of 5, 10 , 15, 20 and 30 minutes with 20 minutes appearing to result in
optimal staining. EDTA antigen retrieval (see Appendix A1.5) resulted in patchy, sub-
optimal staining with this technique.
2.5.5 Primary antibody concentration and incubation time
Both BMP 2 & 6 goat polyclonal antibodies were purchased from Santa Cruz
Biotechnology (BMP-2 sc-6895, BMP-6 sc-7406) and were supplied at 200pg/ml.
The assay was performed for both antibodies with concentrations of primary antibody of
1:80, 1:40 and 1:20. A final working dilution of 1:40 proved optimal for antiBMP-2
which was in-keeping with the findings of Yu et al.140. Staining was best for anti-BMP-6
at a concentration of 20:1.
Sections were incubated with primary antibody at 4°C overnight in a humid
environment. Staining proved inadequate with shorter durations of incubation.
2.5.6 Assay technique
The indirect avidin-biotin complex (ABC) technique was used with the exact method
described in Appendix A1.3. This technique relies upon detection of the biotinylated
secondary antibody by an avidin-biotin-horse radish peroxidase complex. This, in turn,
is identified by utilisation of the reaction between diaminobenzidine (DAB) and
peroxidase which results in production of a visible, insoluble brown product at the site of
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the reaction. This improved sensitivity of this technique compared with other IHC
223methods was shown by Hsu et al.
One negative (primary antibody omitted) and one positive slide (section of rat foetus)
were included with every experimental run.
To ensure positive staining was representative of the presence ofBMP 2 or 6, blocking
peptides were used. The antigens against which the antibodies had been raised were
obtained from Santa-Cruz Biotechnology (BMP-2 blocking peptide sc-6895p, BMP-6
blocking peptide sc-7406p). In accordance with the supplier's instructions, the
antibodies were incubated with their blocking peptide overnight at 4°C with a ratio of
blocking peptide to antibody of 5:1. This solution was then used in place of primary
antibody in the technique described in Appendix A1.3. Suppression of staining was
demonstrated indicating that positive staining was representative of the presence of BMP
2 or 6 (Figure 2.5.1).
2.5.7 Analysis
Three random high power fields (x400) of the mid-fracture specimen were viewed at the
fracture. All positive stained osteoblasts and chondrocytes were expressed as a ratio of
total number of the same cell type visible within the field. Results were expressed using
the Positive Stained Index 224 (expressed as a percentage) which was derived for each
cell type as follows:
Positive Stained Index (PSI) = Positively Staining Cells
Total number of same cell type visible
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The PSI for each field was then scored as follows:
0 = no staining, 1= <25%, 2=25-50%, 3=51-75%
4= >75%
The scores for each field were then added for a total score ranging from 0 to 12 for each
specimen.
It has been shown that the reliability of quantitative immunohistochemical analysis can
be improved by using computerised image analysis 225. Unfortunately this facility was
not available during this study.
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Figure 2.5.1 Efficacy of BMP-2 antibody (sc-6895)
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2.6 Immunohistochemistry for detection of Smad 1
2.6.1 Specimen preparation
Sections prepared in the standard way, as described in Section 2.3, were dewaxed and
rehydrated to distilled water.
2.6.2 Effect of prolonged storage
As in Section 2.5, fresh sections were cut and used in parallel with sections stored for
eight weeks at room temperature. No difference in antigen expression was identified and
stored sections were therefore used.
2.6.3 Antigen retrieval
Antigen retrieval was performed with trypsin solution as described in Appendix A 1.4.
Slides were immersed in trypsin solution at 37°C for 20 minutes. This time was derived
from trials of 5, 10, 15, 20 and 30 minutes with 20 minutes appearing to result in optimal
staining.
2.6.4 Primary antibody concentration and incubation time
The primary antibody used was murine polyclonal anti-Smad 1 (sc-7965, Santa Cruz
Biotechnology) supplied at 200 pg/ml. Dilutions of 1:20, 1:40 and 1:80 were tried with
1:20 representing lOpg/ml final working concentration providing optimal staining.




The assay was run using the Animal Research Kit (ARK) (DAKO) according to the
protocol described in Appendix 1.6. This was used to minimize background staining
which was problematic using the avidin-biotin technique described above.
2.6.6 Analysis
Three random high power fields (x400) were viewed at the fracture. All positive stained
osteoblasts and chondrocytes were expressed as a ratio of total number of the same cell
type visible within the field. Results were expressed using the Positive Stained Index
(expressed as a percentage) which was derived for each cell type as follows:
Positive Stained Index (PSI) = Positively Staining Cells
Total number of same cell type visible
The PSI for each field was then scored as follows:
0 = no staining, 1= <25%, 2=25-50%, 3=51-75%
4= >75%




2.7 5-Bromo-2-deoxyuridine (BRDU) Immunohistochemistry (IHC)
2.7.1 Basis of technique
BRDU is a pyrimidine analogue of thymidine which is incorporated into the
deoxyribosenucleic acid (DNA) of cells in the S-phase of mitosis. Development of
monoclonal antibodies to BRDU has permitted the identification of cells in S-phase of
mitosis using immunohistochemical techniques.
This technique has been shown to be effective in identifying both replicating bone and
cartilage cells in vivo. Farquharson and Loveridge 226 showed that BRDU
immunohistochemistry can be used on both fresh, frozen and fixed and decalcified
sections. Apte 227 validated this assay against thymidine autoradiography for decalcified
tissues and found it to be a useful and reliable technique.
2.7.2 Sample preparation
Animals were labelled by intraperitoneal injection of 25mg BRDU/kg body weight one
hour prior to death. Animals were euthanased and the tibiae were collected, processed,
decalcified and sectioned as described earlier.
Sections were dewaxed and rehydrated through alcohols to distilled water as described
in Section 2.3.
2.7.3 Effect of prolonged storage of sections
Sections were stored in the dark at room temperature for eight weeks prior to carrying
out the BRDU immunohistochemistry. As before, freshly cut sections were stained with
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the experimental sections to establish if storage had effected experimental staining.
There was no difference between stored and freshly cut sections with this technique.
2.7.4 Antigen retrieval
In order to allow exposure of the BRDU antigen the DNA firstly had to be denatured.
This was performed by placing the sections in 2M hydrochloric acid (HCL) at 37°C for
30 minutes. After washing in phosphate buffered saline (PBS) further antigen retrieval
was carried out by placing the sections in trypsin solution at 37°C for 20 minutes (see
Appendix A 1.4).
This method of antigen retrieval was selected as optimum after trials with the following
combinations:
2M HCL for 30 minutes at 37°C followed by trypsin solution for 10, 20 and 30 minutes
5M HCL for 45 minutes at room temperature followed by trypsin solution for 10, 20 and
30 minutes
2M HCL followed by EDTA antigen retrieval technique described in Appendix A 1.5.
The selected technique provided the best staining with minimum background.
2.7.5 Primary antibody concentration and incubation time
The primary antibody used was mouse monoclonal anti-BRDU (IgG, clone BU 33,
SIGMA UK).
The experiment was run using the following dilutions of primary anti-BRDU mouse
monoclonal antibody: 1:125, 1:250, 1:500, and 1:1000. A concentration of 1:250 was
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found to be optimal. This represented a final concentration of 16ug/ml as stock was
supplied at 4000ug/ml.
Sections were incubated with primary antibody in the following conditions: 30, 60 and
120 minutes at 37°C and overnight at 4°C. 120 minutes at 37°C was selected as optimal.
2.7.6 Technique
After specimen preparation and antigen retrieval, the assay was conducted according to
the Animal Research Kit (ARK) (DAKO) protocol shown in Appendix A1.7.
This commercially available kit was used due to problems with excessive background
staining encountered using the indirect staining technique described earlier for the BMP
assays. The ARK is designed to minimise background which may arise due to reactivity
of secondary anti-mouse antibody with endogenous antigen in rodent tissue.
For this assay the diluent used was DAKO antibody diluent.
2.7.7 Analysis
Three random high power fields (x400) were viewed at the fracture site. All positive
stained cells were expressed as a ratio of total number of the same cell type visible
within the field. Results were expressed using the Positive Stained Index which was
derived for each cell type as follows:
Positive Stained Index (PSI) = Positively Staining Cells
Total number of same cell type visible
Scoring was applied as described in Section 2.5.7
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2.8 Verification of the osteopenia model
2.8.1 Confirmation of ovariectomy
After euthanasia and removal of the tibiae the cadavers were dissected to confirm the
absence of ovaries in the ovariectomy animals. Sham models were also dissected to
ensure the ovaries were present.
2.8.2 Uterine weight
All uteri were removed from the cadavers and fixed in formalin. All uteri were then
weighed three times. The mean weight of each uterus was expressed in grammes.
2.8.3 Calculation of bone mineral density
Volume
Volume was calculated using Archimedes' principle . Tibiae were stripped of all soft
tissue and the fibulae removed. The tibiae were then weighed (weight A).
A bijou was filled with water and sealed underwater to ensure the absence of air
bubbles. The filled bijou was then dried externally and weighed (weight B).
The tibia was then placed in the filled bijou which was once again sealed underwater to
ensure the absence of air. The water filled bijou containing the tibia was then externally
dried and weighed again (weight C).
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From the principle that 1ml ofwater weighs lg, the volume of the tibia was calculated
from the following formula:
Weight ofwater in bijou displaced by bone = B - (C - A)
Weight of displaced water (g) = volume of bone (ml)
Ash weight
Tibiae were placed in individual, pre-weighed crucibles and placed in a muffle furnace
at a temperature of 600°C for 24 hours. After cooling, the crucibles plus the ash were
weighed and after subtraction of the crucible weight the ash weight of each bone was
derived. The mean of three repeat measurements was taken as representative.
Bone mineral density (BMD)
BMD was calculated as follows:





The healing fractures were tested by four-point bending as described below. Bending is
a practical and well accepted technique for obtaining biomechanical data about small
animal bones or healing fractures 229. The alternative of tensile testing does provide
accurate assessment of biomechanical properties of both cortical and cancellous bone.
However, the technicalities ofmounting specimens for tensile testing mean that this
requires relatively large or well machined specimens and it is therefore rarely used for
testing rodent bone.
Testing in compression can provide useful information on the mechanical properties of
cancellous bone in particular. It has the additional advantage of reproducing a more
physiological model with for example vertebra normally being under compression in-
vivo. Accuracy relies upon uniform compression being applied and this could not be
achieved to test the proximal tibia in the axial plane due to the geometry of the rat tibia.
• • • • 230 231 . • •
Previous workers have tested healing fractures in torsion ' . This provides
information about the behaviour of the sample in shear. However, the specimen requires
to be circular in cross section so that a constant centre of rotation exists at which shear is
zero. With a non-circular specimen the polar moment of inertia changes during the test
rendering the results inaccurate 229. Once again the shape of the proximal tibia was
thought to be unsuitable for testing in torsion for this reason.
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Bending tests are applicable to small specimens and reproduce an element of the normal
physiological environment under which long bone fractures heal. Bending a bone results
in tension on one side and compression on the other with failure usually occurring on the
tension side as bone is weaker in tension than compression 232. Bending can be achieved
using three or four contact points. Three point bending is simple to perform but results in
significant shear at the mid-loading point . This problem is compounded by the fact
that small specimens result in a low span to depth ratio as biological specimens are of a
predetermined length and depth. A span to depth ratio of greater than 16 is
recommended to exclude shear but this cannot be achieved with rodent tibia or femur.
Four point loading results in minimal shear between the two mid-loading points. It does
however rely on equal contact by all four loading points which is elementary on
standardized samples but can be more difficult with bone. For this reason a pivot is
usually incorporated into the design of the loading contact to ensure constant contact
throughout. On this basis, it was decided to design apparatus to test specimens in four-
point bending to failure.
2.9.2 Retrieval and storage of samples
In order to reduce error, all samples were stored and tested in one experimental run. It
has previously been shown that bone can be frozen in saline at -20°C and thawed out
without affecting material or mechanical properties 234.
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Immediately after euthanasia both tibiae were dissected free of all soft tissue with
disarticulation of the tibiofemoral and tibiotalar joints. The intramedullary pins were
removed and the samples immersed in 0.9% normal saline (NaCl). Samples were then
frozen to -20°C in a standard freezer. Storage time under these conditions varied from 1
to 3 weeks to accommodate the two experimental time points.
2.9.3 Preparation of samples for testing
All samples were removed from the freezer and placed within their saline filled
containers into a water bath set at 37°C. Adequate thawing of the samples was ensured
by verifying saline temperature had reached 37°C for 30 minutes prior to mechanical
testing. During the thawing period the fracture calluses were measured in the antero¬
posterior and medio-lateral planes using a precision calliper measuring to 0.1mm. The
mean of three readings was taken for each orientation for each sample. Samples were re-
immersed in the warmed saline for a further five minutes then removed and immediately
tested to failure. On average the total time from removal from saline to end of the
experiment was 90 seconds.
2.9.4 Testing apparatus and specification
All tibiae were tested to failure by four-point bending using a Instron materials testing
machine (Series 4500, Instron Corp. Canton, Mass, USA).
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The four point loading jig shown in Figure (2.9.1) was designed and produced
specifically for this work by University ofEdinburgh Engineering Workshop, Kings
Buildings, Edinburgh.
The upper loading assembly was designed to incorporate a pivot to ensure symmetrical
loading by the upper two contacts. The upper loading span was 5mm and the lower,
static span was 20mm. Contact points were rounded to minimise notching of the bone
after application of load.
All samples were tested in the same orientation with the tibiae resting on their lateral
surface and the force being applied from the medial aspect. The tibiae were found to be
stable in the testing apparatus in this orientation after a trial or various different
orientations.
Testing specifications were as follows:
Load cell 500N
Rate of deformation 2mm/minute






Thirty tibiae from the cadavers of rats weighing between 300g and 400g were collected,
frozen, thawed then tested using the above criteria. This allowed assessment of the
reliability of the testing method. The results are shown in Appendix 3.7. Standard
environmental conditions have been shown to be important with changes in humidity
• • 990
and room temperature known to influence material testing results
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2.9.5 Expression of Results
Data derived from the materials testing machine was expressed as load (N) / deformation
(mm). Load at yield and failure were taken directly from the load / deformation graph
with yield defined as the point were the load /deformation curve became non-linear.
Load at failure was defined as the maximum load applied. Extrinsic stiffness was
calculated from load / deformation at the point of yield.
Other workers have directly measured the cross sectional area of the fracture plane using
image analysis and pixilation 213. This highly accurate technique was not available and
the cross sectional area was therefore estimated from biplanar measurements taking the
fracture plain as an ellipse.
The area of an ellipse is:
Width x 71 x (Height/4)
The cross sectional moment of inertia (/) is a measure ofmaterial distribution around a
neutral axis. In order to calculate stress, / must be known.
Cross sectional moment of inertia for an ellipse:
Iy = Va x n x vertical radius x horizontal radius3
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Figure 2.9.2 allows interpretation of the following formulae
Figure 2.9.2 Diagram of four point bending model
Methods
(F=force, displacement, L=span, a=distance from outer to inner contact)
Stress can therefore be calculated from:
Stress (a) = (force x a x c) / 2/
(c = distance from the centre of the mass or half the height of the callus)
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Strain describes the deformation of an object under load and is expressed as new length /
original length. For bone which undergoes relatively small degrees of strain, this is
usually expressed as pstrain. Strain can be measured directly using a strain gauge or
derived from load/deformation data for four point bending as follows 229:
Strain (s) = (6 x vertical radius x displacement)
a(3L - 4a)
Young's Modulus (E) was calculated from the data as follows:
E = (force/displacement) x (a2/127) x (3L-4a)




(7) Moment of inertia (mm4)
(a) Stress megapascals (Mpa) (1 Pascal = 1 Newton/m2)
(e) Strain pstrain
(E) Young's Modulus gigapascals (GPa)
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Energy to yield Megajoules MJ




Data were compared using the statistical package Graphpad (Graphpad Software Inc. El
Camino Real, San Diego, USA).
The individual tests used in each analysis are given with the results in Section 3.
Consideration was given to the application of Bonferroni's correction to various multiple
analyses carried out in this work. While the use of the correction to avoid inadvertent
Type 1 errors is appropriate in certain circumstances it was considered that the
interdependence of the data made the use of the correction inappropriate. The use of
Bonferroni's correction in the multiple analyses of interdependent data has been shown
to excessively reduce the power of studies where multiply analysed data are
interdependent. It remains the case however that where p values are close to an alpha of
0.05 the significance of the result should be interpreted with caution due to the
theoretical risk of type one errors in such analyses.
2.11 Power calculation
The sample size of five per outcome group (five for histology and five for mechanical
testing equalling ten per group) was chosen based on a power analysis of the following
parameters:
Evaluation of a 30% difference
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Estimated from previous work by Walsh et al. 210 and Namkung-Matthai et al.
Alpha = 0.05
Beta = 0.8
Samples of unequal variance, Sigmai=12, Sigma2 = 7
Gives ni = 4.487, n2 = 2.513





3.1 Confirmation of the osteopenic model
3.1.1 Uterine weight and histology
The mean uterine weight from the ovx animals was 57% of the mean of the sham
animals (Figure 3.1.1.1). This difference was significant when tested with an unpaired,
two-tailed t-test (p<0.0001).
H & E sections of randomly selected uteri from sham and ovx animals showed marked
endometrial and myometrial atrophy in the specimens from the ovx group (Figure
3.1.1.2 & 3.1.1.3).
The significant reduction in uterine weight and tissue atrophy confirmed the efficacy of














Creation of fracture occurred eight weeks after ovariectomy or sham procedure. As
expected, by this time the ovx animals had gained weight and had a significantly higher
mean body weight than sham animals. The mean weight of all ovx animals at the time of
fracture was 365.07g compared with 299.75g for sham animals (p<0.001, un-paired two
tailed, t-test). Mean body weight was unchanged in all groups during the first two weeks
after fracture as shown in Table 3.1.2.1.
The mean body weights of the groups euthanased at four weeks had however increased
significantly. Once again, the ovx animals had gained the most weight since the time of
fracture (mean gain 41.6g for ovx versus 20.07g for sham, p<0.001, unpaired, two tailed
t-test). This would suggest that weight gain occurs during weeks 2 to 4 following
fracture.




Table 3.1.2.1 Body weights for animals euthanased at two weeks post
fracture
Time of fracture Two weeks post fracture P value
Weight (g) SD Weight (g) SD
Sham &
placebo B1
307.38 13.1 300 17.4 0.105
Ovx &
placebo B2
371.11 25.2 359.44 29.9 0.340
Sham &
statin B3
293.01 15.7 286.2 13.69 0.445
Ovx &
statin B4
363.2 22.7 364.8 27.6 0.762
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Table 3.1.2.2 Body weights for animals euthanased at four weeks post
fracture
Time of fracture Four weeks post fracture P value
Weight (g) SD Weight (g) SD
Sham &
placebo A1
298.75 27.0 322.38 27.4 0.0207
Ovx &
placebo A2
367 29.1 410.4 27.5 0.0021
Sham &
statin A3
288.89 11.7 315.4 18.8 0.0192
Ovx &
statin A4
359 15.2 398.8 18.3 0.0001
Data tested with unpaired, two tailed t-test. Normal distribution of data confirmed
using Kolmogorov Smirnoff method.
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3.1.3 Tibial ash weight, volume and mineral density
The data shown in Table 3.1.3 were derived using the techniques described in section
2.8.3. While mean ash weight of the tibiae was the same in the ovx group and sham
controls, the mean volume was higher in the ovx group. This resulted in a significantly
lower mean tibial bone mineral density in the ovx group compared with sham control.
This confirmed that eight weeks after ovariectomy the rat tibiae had become osteopenic.
This is illustrated in Figure 3.1.3.
Table 3.1.3 Ash weight, volume and bone mineral density of tibiae
All sham animals All ovx animals P value




0.318 0.004 0.310,0.326 0.312 0.004 0.303,0.320 0.766
Volume
(cm3)
0.436 0.007 0.421,0.451 0.476 0.011 0.452,0.500 0.0226
BMD
(g/cm3)
0.729 0.006 0.719,0.744 0.662 0.013 0.635,0.689 0.0137
BMD = bone mineral density, SEM = standard error of the mean,
CI = confidence interval




Figure 3.1.3 Tibial bone mineral density of animals 8-10 weeks post



















3.2 Results of Part 1
Fracture healing in the ovariectomy model versus sham control
3.2.1 Exclusions (sham v ovx)
A total of five out of the 40 (12.5%) animals in this arm of the study were excluded. A
summary of exclusions per group is shown in Table 3.2.1. The most frequent problem
was creation of an unsatisfactory fracture. In one case this was identified at the time of
fracture creation by palpation of obvious comminution and failure to obtain stabilisation
with the intramedullary wire. This animal was euthanased while under anaesthesia. In
the two other cases unsatisfactory comminution was identified on radiographs following
euthanasia and the specimens were discarded.
In two cases, stabilisation had been lost following creation of satisfactory fractures. This




Table 3.2.1 Exclusions in the sham & placebo and ovx & placebo groups
Group Description Exclusions Reason for Exclusion
B1 Sham & placebo,
Two weeks
2/10(20%) 1 - unsatisfactory fracture
2 - loss of stabilisation
B2 Ovx & placebo, two
weeks
1/10(10%) 1 - unsatisfactory fracture
A1 Sham & placebo,
Four weeks
2/10(20%) 1 - unsatisfactory fracture
2 - loss of stabilisation






A lower proportion of trabecular and lamellar bone was present at the fracture site in the
ovx model compared with sham control two weeks following fracture. Although no
statistically significant differences were seen between proportions of other tissue types a
trend towards an increased amount ofwoven bone and marrow in the ovx model was
noted at two weeks.
By four weeks post fracture the trend towards an increased proportion ofmarrow at the
fracture site in the ovx model had become statistically significant. This was compensated
for by a continued, significant reduction in the proportion of trabecular or lamellar bone
present. The four week old callus in the ovx model therefore appeared more porous with
a lower proportion of calcified material present overall.
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Table 3.2.2.1 Summary of histological tissue types at the fracture site at two
weeks post fracture (sham versus ovx). Results expressed as percentage of










39.27 1.76 26.93 5.07 0.022
Woven bone 40.14 3.20 51.90 5.83 0.106
Cartilage 8.50 2.29 5.07 1.27 0.170
Marrow 8.76 2.98 12.99 4.37 0.713
Undifferentiated 4.36 2.05 3.11 0.99 0.967




Table 3.2.2.2Summary of histological tissue types at the fracture site at four
weeks post fracture (sham versus ovx). Results expressed as


























• Statistical comparison made using unpaired two tailed t-test. Data tested for
normality using Kolmogorov-Smirnoff test.
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3.2.3 Radiological Results (sham v ovx)
Radiographs of the healing tibial fractures from the groups euthanased at 2 weeks (B1 &
B2) showed calcifying external callus but the persistence of complete fracture lines in all
specimens (Figure 3.2.3.1).
At the four week time point the presence of a fracture line on the radiographs was more
variable. This variability however appeared to be similar in both groups (A1 & A2). The
presence of fracture line was scored according to the method described in Section 2.4
but no significant difference in scores existed between groups A1 and A2. Results for
scoring of these two groups are shown in Table 3.2.3 with an example of the radiological
appearance of the healing fractures at four weeks shown in Figure 3.2.3.2.




A1 Sham & placebo 2.5 1-4 0.1505
A2 Ovx & placebo 3.0 2-4




Typical radiographic appearance of healing fractures in all
groups two weeks post fracture
Figure 3.2.3.2 Typical radiographic appearance of healing fractures in all
groups four weeks post fracture
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3.2.4 Immunohistochemistry results (sham v ovx)
The results of staining for BMP 2 and 6, Smad 1 and the marker of proliferation BRDU,
are summarised in Tables 3.2.3.1 and 3.2.3.2. Staining for each of the antigens was seen
mainly in osteoblasts and chondrocytes two weeks following fracture. By four weeks
following fracture chondrocytes were sparse and as a result only osteoblasts were scored
for antigen expression at this time point.
3.2.4.1 BMP - 2 expression
Cytoplasmic staining for the BMP-2 antigen was seen in osteoblasts and chondrocytes at
the healing fractures from both sham and ovx groups at two weeks. The number of
positively staining cells varied within each group. Typical examples are shown in Figure
3.2.4.1.
No statistically significant difference was seen between the scores for BMP-2 expression
at two or four weeks in osteoblasts when comparing the sham versus the ovx groups.
Similarly, no difference existed in the expression of BMP-2 in fracture site chondrocytes
from either group two weeks following fracture.
No staining for BMP-2 was seen in the periosteum in either group.
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3.2.4.2 BMP - 6 expression
Cytoplasmic staining was seen for BMP-6 antigen at both two and four weeks in the
osteoblasts from both groups with no significant difference found in the number of cells
staining positively in each group. Staining for BMP-6 was also seen in the cytoplasm of
chondrocytes within the fracture callus two weeks following fracture but no difference
existed between ovx or sham groups for the extent of positive staining in this cell
population.
3.2.4.3 Smad- 1 expression
As with BMP 2 and 6, strong staining was seen in the cytoplasm of both osteoblasts and
chondrocytes in the fracture callus of specimens from both ovx and sham groups two
weeks following fracture. Fracture site osteoblasts continued to express Smad-1 four
weeks following fracture but again no difference was seen in the degree of expression
between either sham or ovx groups.
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Group A1 (sham & placebo), light x400
Group A2 (ovx & placebo), light x400
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3.2.4.4 Bromodeoxyuridine (BRDU) expression
Strong nuclear staining was seen in chondrocyte and osteoblast populations in the
fracture callus from both sham and ovx groups. This is shown in Figures 3.2.3.2-4.
Positive staining in the periosteum was sparse in all specimens. Quantification of
positive staining revealed no difference between sham and ovx groups for expression of
BRDU in osteoblasts at either time point, or chondrocytes at two weeks post fracture.
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Figure 3.2.4.2 Specimen from group B1 (sham & placebo) showing
positive staining for BRDU in osteoblasts and chondrocytes
at the healing fracture site two weeks post fracture
Figure 3.2.4.3 Specimen from group A1 (sham & placebo) showing
positive staining for BRDU in osteoblasts at the healing
fracture site four weeks post fracture (light x200)
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Figure 3.2.4.4 Specimen from group B1 (sham & placebo) showing
positive staining for BRDU in chondrocytes at the fracture
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3.2.5 Results of mechanical testing (sham v ovx)
The following data has been derived from the load / displacement curves generated by
testing the healing fractures in four-point bending to failure. The method is described in
Section 2.9. The intrinsic properties of stress, strain, Young's modulus and energy to
yield have all been calculated from the formulae described in Section 2.9.5.
The data is summarised in Table 3.2.5.1 for the healing fractures two weeks post
creation of fracture (groups B1 and B2) and Table 3.2.5.2 for those at four weeks post
creation of fracture (groups A1 and A2).
Unfortunately two specimens from both two week time point groups were excluded due
to loss of position on the testing apparatus during initial loading. Data are presented for
reference in Table 3.2.5.1 expressed as mean with 95% confidence intervals.
3.2.5.1 Load at yield and failure
At two weeks post fracture there was no difference between the sham or ovx groups in
the mean load applied at the points of yield or failure. The load at the point ofyield had
increased in both groups by four weeks post fracture. By this time the load at yield in the
ovx group was only 71% that of the load at yield of the sham group. The same result was
found for the load at failure with the healing fractures in the ovx animals withstanding
only 71% of the load at failure of the sham group four weeks after fracture creation.
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Both of these differences were statistically significant and are illustrated in Figures
3.2.5.1 and 3.2.5.2.
3.2.5.2 Stiffness
The mean stiffness of the healing fractures at two weeks was similar in both sham and
ovx groups. By four weeks however, a statistically significant difference in the stiffness
was seen with the mean stiffness of the healing fractures in the ovx group being
approximately 54% that of the sham group. These findings are illustrated in Figure
3.2.5.3.
3.2.5.3 Callus area and moment of inertia
Callus area was estimated by the method described in Section 2.9.5. The calluses
decreased slightly in size between two and four weeks post fracture but no significant
difference was seen between callus areas in the sham or ovx groups at either time point.
No difference was seen in the moments of inertia in either group or time point reflecting
the similar callus areas and distribution ofmaterial.
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3.2.5.4 Intrinsic mechanical properties of the healing fractures
At two weeks post fracture the stress and strain at the point of yield were the same in
both sham and ovx groups. As Young's modulus and energy to yield are calculated
directly from these data they did not differ either.
By four weeks post fracture, the stress at yield was significantly greater in the sham
group compared with the ovx group. The inverse was true however of the strain at yield
with the ovx fractures withstanding 140% of the strain of the sham fractures before
yielding. This resulted in the four week old healing fractures in both groups absorbing
approximately the same mean energy before yield. This is illustrated in Figure 3.2.5.4
which plots the mean stress and strain for both groups to show a model of the linear
portion of the groups' stress / strain curves.
The moduli of the healing fractures were low in both groups at both time points. The
moduli did increase between two and four weeks but the increases were not significant
in either group. Although the mean modulus of the four week old healing fractures in the
sham group was 146% of the mean modulus in the ovx group this difference was also
not significant.
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Figure 3.2.5.1 Mean Load at Yield (sham v ovx)
2 weeks 4 weeks
Time post fracture
Figure 3.2.5.2 Mean Load at Failure (sham v ovx)
120 1




Figure 3.2.5.3 Mean Stiffness (sham v ovx)
200 i
2 weeks 4 weeks
Time post fracture
Figure 3.2.5.4 Linear portion of stress / strain curve of healing
fractures at four weeks post fracture (sham v ovx)
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3.3 Results of Part 2
The effect of simvastatin on fracture healing in normal and
osteopenic bone
3.3.1 Exclusions
Only one specimen was excluded from this section of the study. This specimen was from
group A3 and was excluded due to unsatisfactory fracture pattern as defined pre-test but
seen post mortem.
3.3.2 Histological results
The data from histological analysis of the fracture calluses in both groups given
simvastatin versus placebo are summarised in Tables 3.3.2.1 to 3.3.2.4.
In the sham model, no difference was seen in the proportion of tissue types present two
weeks following fracture. However by four weeks post fracture a difference was seen in
the amount ofwoven bone still present at the fracture sites of sham animals given
simvastatin compared with placebo. The statistical significance of this finding with a p
value of 0.029 is questionable in a multiple analysis of this kind but simvastatin did
appear to result in decreased maturity of the callus in the sham animals.
In the ovx group a similar picture was seen. At two weeks post fracture simvastatin
treatment the histological appearance of the fracture callus was not significantly
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different compared with the control. By four weeks however a more immature callus
was once again seen in the simvastatin treated group. An even greater proportion of
woven bone compared to trabecular or lamellar bone was seen than had been noted in
the sham model. Simvastatin treatment had again resulted in a less mature callus but this
effect appeared to be exaggerated by ovariectomy. As mentioned previously, the
statistical significance of these findings is not certain due to the risk of a type one error
in such analyses but a trend towards reduced callus maturity was certainly apparent.
Table 3.3.2.1 Summary of histological tissue types at the fracture site at two
weeks post fracture (simvastatin v placebo) in sham model.
Results expressed as percentage of total number of graticule points










39.27 1.76 36.93 5.78 0.659
Woven bone 40.14 32.0 38.24 1.65 0.600
Cartilage 8.50 2.29 6.41 1.46 0.450
Marrow 8.76 2.98 9.97 3.1 0.772
Undifferentiated 4.36 2.05 8.44 2.15 0.134
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Table 3.3.2.2Summary of histological tissue types at the fracture site at four
weeks post fracture (simvastatin v placebo) in sham model.
Results expressed as percentage of total number of graticule points



























Table 3.3.2.3Summary of histological tissue types at the fracture site at two
weeks post fracture (simvastatin v placebo) in ovariectomised
model.
Results expressed as percentage of total number of graticule points

























Table 3.3.2.4Summary of histological tissue types at the fracture site at four
weeks post fracture (simvastatin v placebo) in ovariectomised
model.
Results expressed as percentage of total number of graticule points




























Radiographs of the tibiae two weeks post fracture showed persistence of complete
fracture lines throughout all the groups.
Variability did exist within all groups with regard to the degree of presence of fracture
line in the tibiae four weeks post fracture. In both sham (A3) and ovx (A4), simvastatin
supplementation resulted in no significant radiological difference in presence of fracture
line when compared with placebo using the Mann Whitney U Test. Results are
summarised in Table 3.3.3.1.
Table 3.3.3.1 Summary of scores for presence of fracture line seen on
radiographs four weeks post fracture
Placebo Simvastatin P value
Group median Group Median
Sham A1 2.5 A3 3.0 0.085
Ovx A2 3.0 A4 3.0 0.591
3.3.4 Immunohistochemistry results
This section compared the expression of BMP 2, 6, Smad 1 and the marker of
proliferation BRDU in sections from the fracture calluses of sham and ovx animals fed
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either simvastatin or placebo. For the factors BMP 2, 6 and Smad 1 sporadic
cytoplasmic staining was seen in osteoblasts and chondrocytes. Strong BRDU staining
was seen in the nuclei of osteoblasts and chondrocytes indicating these cells were
undergoing replication.
A summary of the results from this section is shown in Tables 3.3.4. lto 3.3.4.4.
3.3.4.1 BMP-2 expression
Supplementation with simvastatin made no difference to BMP-2 expression in the
osteoblasts or chondrocytes at the fracture sites in sham animals. Cytoplasmic staining
was present in both groups to an equal degree at two and four weeks post fracture.
The same was true of BMP-2 expression in specimens from ovx animals with
simvastatin supplementation appearing to make no difference to the amount of positive
staining seen at either time point compared with placebo.
3.3.4.2 BMP - 6 expression
Cytoplasmic staining was seen in approximately 25 to 50% of osteoblasts and
chondrocytes at two and four weeks post fracture in both the sham and ovx animals fed
placebo or simvastatin (see Figure 3.3.4.1). There was no statistical difference between
any of the groups for the amount of positive staining for BMP-6.
3.3.4.3 Smad-1 expression
The expression of Smad-1 in osteoblasts at the fracture site was similar to the levels of
expression ofBMP-2 with between 25 to 50% of cells staining positively. No
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differences between any of the groups existed in the proportion of osteoblasts expressing
Smad-1 at two or four weeks (Figure 3.3.4.2).
Flowever in the chondrocytes present in the fracture callus two weeks following fracture
the level of expression of Smad-1 varied. In ovx animals an increased proportion of
chondrocytes stained positively for Smad-1 in the simvastatin group compared with
placebo (see Table 3.3.4.4 and Figure 3.3.4.3). A trend towards a similar result was
noted in the sham animals when comparing those fed simvastatin with placebo but this
did not achieve statistical significance (P=0.0758).
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Group A1 (sham & placebo), light x 400
Group A3 (sham & simvastatin), light x 400
125
Results
Figure 3.3.4.2 Smadl staining in osteoblasts four weeks post fracture
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Group A2 (ovx & placebo), light x 400
Group A4 (ovx & simvastatin), light x 400
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Figure 3.3.4.3 Smadl staining in chondrocytes two weeks post fracture
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Fracture site chondrocytes from group B2 (ovx & placebo), Light x 400
Fracture site chondrocytes from group B4 (ovx & Simvastatin), light x 400
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3.3.5 Results of mechanical testing
3.3.5.1 Simvastatin versus placebo in sham animals
The following data have been derived from the load / displacement curves generated by
testing the healing fractures in four-point bending to failure. The method is described in
Section 2.9. The intrinsic properties of stress, strain, Young's modulus and energy to
yield have all been calculated from the formulae described in Section 2.9.5.
The data is summarised in Table 3.3.5.1.1 for the healing fractures two weeks post
creation of fracture (groups B1 and 3) and Table 3.3.5.1.2 for those at four weeks post
creation of fracture (groups A1 and 3).
Two specimens from group B1 were excluded due to loss of position during initial
loading. Unfortunately one specimen from group A3 had to be excluded for the same
reason making a total of 15% exclusion of samples in this section.
3.3.5.1.1 Load at yield and failure
The loads applied at both the points of yield and failure were lower in the simvastatin
group compared with placebo. However the differences were small and did not achieve
statistical significance. At four weeks post fracture the loads applied at the points of
yield and failure were the same. These results show that simvastatin had no effect on
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ability of the healing fractures in sham animals to withstand load at two or four weeks
post fracture.
3.3.5.1.2 Stiffness
While the mean stiffness of the healing fractures appeared slightly greater in the
simvastatin group the difference was not statistically significant at either two or four
weeks post fracture.
3.3.5.1.3 Callus area and moment of inertia
The cross sectional area of the calluses did not differ between simvastatin or placebo
groups at either two or four weeks. The calculated cross sectional moment of inertia was
also the same in each group and time point.
3.3.5.1.4 Intrinsic mechanical properties of the healing fractures
Although the stress and strain at yield two weeks following fracture appeared to be
lower in the simvastatin group, no statistical difference was demonstrated. Analysis was
however limited by the small sample size in group B1. The sample size necessitated
comparison of the groups using non-parametric testing which increases the likelihood of
a type two error. Table 3.3.5.1.1 shows that the 95% confidence intervals of the mean
stress at yield do not overlap. This suggests a possible effect of simvastatin reducing the
mean stress at the point of yield of healing fractures in the sham operated groups.
There was no difference between simvastatin or placebo groups in mean stress or strain
at yield by four weeks after fracture.
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The moduli of the healing fractures were equal by four weeks post fracture.
The simvastatin group absorbed 43% of the mean energy before yield of the placebo
group. This difference had however disappeared by the time the healing fractures were
four weeks old.
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Figure 3.3.5.1.1 Mean Load at Yield











2 weeks 4 weeks
Time post fracture
Figure 3.3.5.1.2 Mean Load at Failure
(sham animals, statin v placebo)




Figure 3.3.5.1.3 Mean Stiffness
(sham animals, statin v placebo)
250 n
2 weeks 4 weeks
Time post fracture
Figure 3.3.5.1.4 Linear portion of stress / strain curve of healing
















3.3.5.2 Results of simvastatin versus placebo in ovariectomised animals
The following data has been derived from the load / displacement curves generated by
testing the healing fractures in four-point bending to failure. The method is described in
Section 2.9. The intrinsic properties of stress, strain, Young's modulus and energy to
yield have all been calculated from the formulae described in Section 2.9.5.
The data is summarised in Table 3.3.5.2.1 for the healing fractures two weeks post
creation of fracture (groups B2 and B4) and Table 3.3.5.2.1 for those at four weeks post
creation of fracture (groups A2 and A4).
As mentioned previously, interpretation of results in this section was hindered by the
necessary exclusion of specimens due to loss of position on the mechanical testing
apparatus. For this reason, two specimens were excluded from group B2 and one from
group B4.
3.3.5.2.1 Load at yield and failure
The values for mean load at yield and failure were lower at the two week time point in
the ovx group fed simvastatin compared with placebo. Wide confidence intervals
however reflect large standard deviations for these mean values and no statistical
difference was seen between the groups at two weeks following creation of fracture. By
four weeks post fracture creation the mean load at failure was significantly lower in the
simvastatin group compared with placebo (Figure 3.3.5.2.2). The mean load at the point
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of yield was also lower in the simvastatin group at this time point but the difference did
not achieve statistical significance.
3.3.5.2.2 Stiffness
No significant difference was seen in the mean stiffness of the healing fractures at either
two or four weeks following fracture. Mean values were however, again reduced in the
simvastatin groups compared with placebo at four weeks post fracture (Figure 3.3.5.2.2).
3.3.5.2.3 Callus area and cross sectional moment of inertia (CSMI)
At two weeks following fracture there were no differences in the mean callus area or
CSMI between the simvastatin or placebo groups. By four weeks however, the callus
size and CSMI were both significantly smaller in the simvastatin fed group. The mean
callus size in the simvastatin group was only 57% that of the placebo fed animals.
3.3.5.2.4 Intrinsic mechanical properties of the healing fractures
Interpretation of the intrinsic mechanical data from the two week time point is hindered
by the small sample sizes in groups B2 and B4. No clear differences were seen between
the groups for mean stress, strain, energy to yield or Young's modulus.
By four weeks following fracture significant differences between the groups were seen.
Both stress and strain at the point of yield were reduced by 43% and 30% respectively in
the simvastatin group. This was reflected in a 60% reduction in the energy absorbed
prior to yield in the simvastatin fed group compared with placebo. This can be seen by
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the different areas under the lines in Figure 3.3.5.2.4 where the mean stress and strain at
yield have been plotted for values four weeks post fracture. Figure 3.3.5.2.4 does not
however show a clear difference in the slope of the lines yet Young's modulus
calculated by the method described in section 2.9 differed significantly between the
simvastatin and placebo groups. The mean modulus of the healing fractures prior to
yield in the simvastatin group was only 26% of the mean modulus in the placebo group.
Feeding with simvastatin at 20mg/kg for two weeks following fracture appeared to
impair significantly the mechanical properties of the healing fractures in the ovx groups.
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Figure 3.3.5.2.1 Mean load at yield
(OVX animals, statin v placebo)
JL.
JL,




Figure 3.3.5.2.2 Mean load at failure





















Figure 3.3.5.2.3 Mean Stiffness
(OVX animals, statin v placebo)
n placebo
n Statin
2 weeks 4 weeks
Time post fracture
Figure 3.3.5.2.4 Linear portion of stress / strain curve of healing fractures





Fragility fractures in humans are becoming increasingly common and will present an
ever increasing burden on health care for the foreseeable future. Advances in the current
limited understanding of the process of fracture healing in osteoporosis could have
significant benefits and translate into improved management of this large patient group.
There is no doubt that prevention is better than cure and attention is deservedly directed
towards pharmaceutical and lifestyle interventions to reduce the incidence of fragility
fractures. The process of bone healing is however integral to the development of
fragility fractures as it is the altered bone turnover and resulting development of
microfracture that ultimately facilitates clinical fracture in these individuals.
Additionally, even with the best currently available preventative measures, the incidence
of fragility fracture remains high and advances in treatment should continue to be
sought.
The primary objective of this study was to compare the early stage of fracture healing in
osteoporotic bone versus non-osteoporotic bone and establish if clinically relevant
differences existed. Processes believed integral to fracture healing were also investigated
in an attempt to elicit possible mechanisms for any differences demonstrated.
The exciting early results ofMundy et al. 65 and Skoglund et al. 183 showing a
potentially beneficial effect of simvastatin supplementation on bone formation created
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the prospect of a direct role for this simple pharmacological intervention in fracture
healing. These results were however controversial and had not been applied to the
setting of fracture healing in osteoporosis. The second part of this study was therefore
designed to investigate further the role of simvastatin in fracture healing and its
application in osteoporotic fracture.
4.1 The fracture model
The most appropriate model to study is the human but as with many studies
impracticalities existed in attempting to use humans for this investigation. Obtaining
tissue from healing human fractures which required no operative intervention was
ethically questionable. Controlling for factors such as comorbidity, age, sex and fracture
configuration would have required recruitment of very large numbers and mechanical
outcome measures are not yet well defined in the field of human fracture repair.
Attempts should continue to be made however to study the human wherever possible
and certainly analysis of human systemic markers, bone and callus will provide us with
the most relevant information in the future.
The rat model overcomes many of the problems mentioned above which is why it is a
commonly used and accepted model for the study of fracture repair. As with all animal
models however, some limitations had to be accepted. Perhaps the most important
consideration was the difference in skeletal maturity between the three-month old rat
and the mainly elderly human population to whom these data would be applied. Rats do
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not reach skeletal maturity and their growth plates remain open. Longitudinal bone
growth therefore continues and the additional impact of senescence occurring in
osteoporotic humans 235 was not reproduced by the rat model used in this study. An
attempt to minimise the impact of this was made by using rats beyond adolescence but
an effect from the continued growth stimulus on fracture healing in the model must be
considered when extrapolating from this data. Similarly, the local fracture environment
in the model differed from that of the common osteoporotic fractures in humans. In
elderly humans, reduced vascularity and poor soft tissues are often a feature which was
not the case in the model. Additionally the creation of an acceptable, standard fracture in
the model required an open technique while most human osteoporotic fractures are
closed.
A strength of this study was the use of a cancellous fracture model. Most fragility
fractures in humans occur in bone metaphyses and the applicability of the more
commonly studied mid-diaphyseal models is questionable. Creation of a standard,
transverse fracture in the proximal tibia proved more difficult than creating a mid-
diaphyseal fracture but careful development of the technique resulted in few exclusions.
This fracture model appears to be entirely novel in the investigation of fracture healing
in osteopenia, yet it showed similar degrees of impairment of fracture healing in the
osteopenic animals when compared with diaphyseal models. One of the major
drawbacks of the use of the rat for studying fracture healing is that osteonal healing does
not occur. This would certainly influence cortical healing but may be of lesser
importance in a cancellous bone fracture such as the one used here.
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The use of intramedullary fixation did not confer absolute stability to the fracture but as
rigid fixation is not commonly used in the operative treatment of osteoporotic fracture,
this was felt to be a suitable and practical technique for maintaining the consistent
fracture alignment required for meaningful mechanical testing. While a closed fracture
with no operative fixation would be a purer model for the study of fracture repair the
inconsistency of fracture configuration and position at union meant that this model could
not be used.
4.2 The ovariectomised rat as a model for osteoporosis
Many investigators have used the castrated female rat for studying the effects of the
anoestrous environment. It has been widely accepted as an appropriate model for the
study of "osteoporotic" bone with pronounced decreases in bone mineral density seen a
few weeks after ovariectomy. Caution must be exercised however, when using this
model. The timing of the index intervention following ovariectomy is crucial and
adequate time must be allowed to elapse to ensure a steady state of bone turnover has
occurred. Intervention too early would introduce the potentially confounding effects of
inadequate loss of bone mineral density against the background of the rapid bone
resorption which occurs in the first four weeks post ovariectomy75. Allowing seven
weeks to elapse prior to fracture creation in this study was considered adequate.
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The degree of osteopenia induced by ovariectomy is difficult to compare with the human
situation and a definition for osteoporosis in the rat does not exist. Measurement of bone
mineral density varies depending on the method used and no population data is available
for the rat making it impossible to derive a T-score in this species. It is therefore more
accurate to refer to the model as osteopenic rather than osteoporotic. It is also important
to note that spontaneous fractures do not occur in the ovariectomised rat as they do in
the osteoporotic human 204. There is however no doubt that the ovariectomised rat does
provide a useful model to study fracture repair in the anoestrous environment with the
effects of oestrogen withdrawal on bone and the reproductive tract being confirmed in
this study.
The use of the sham operated control is of great importance. The effect of stress on
oestrogen levels can be pronounced and unpredictable and the stress of surgery,
transport and environment must be controlled for. Difficulty exists in controlling for the
weight gain which results following ovariectomy due to accumulation of adipose tissue
2I3. In this study the decision not to pair feed resulted in ovariectomised animals being
approximately 20% heavier than control. This will have resulted in differential loading
of the healing fractures which was not controlled. Pair feeding however results in
animals being in a constant state of hunger which translates into stress and a resulting
hormonal disturbance. This would have had unpredictable results and pair feeding was
therefore not employed as it has not been in many other similar studies.
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4.3 Fracture healing in the ovariectomy model versus control
This study provided clear evidence for a deleterious effect on early fracture healing of
the osteopenic / anoestrous environment. The substantial reduction in ability to
withstand load to the point of yield and failure in the fractures from osteopenic bone
compared with control complies with the previous findings ofWalsh et al. 210 and
Namkung et al. 21 \ These investigators used very similar methods with the exception
that their models were of femoral, mid-diaphyseal fractures. This implies that the cause
of the poorer mechanical properties of osteopenic fracture callus is a mechanism
common to diaphyseal and metaphyseal healing. Deficiencies therefore seem less likely
to be primarily related to altered vascularity or angiogenesis as cancellous bone is
known to benefit from a significantly more abundant blood supply than cortical bone.
The fact that both cortical and cancellous bone healing are affected implicates the
process of osteogenesis as the main factor influenced by an ostepenic environment as it
is the major process common to the healing of both types of bone. In the diaphyseal
fracture model of Bonnerans and Einhorn192 endochondrial ossification predominates
initially whereas in the metaphyseal model a greater proportion of intramembranous
ossification should be expected where fracture fragment contact occurs. It is possible
that osteopenia affects both processes but the step common to both is the production and
maturation of calcified material and this should be the focus of further work in this field.
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Histologically there was a higher proportion ofwoven bone to trabecular bone in the
early stages of healing with a subsequent increased porosity in the osteopenic fracture
callus at four weeks. This suggests a decreased maturity which might translate into
decreased ability to withstand load, particularly in compression. The hypothesis that the
poorer mechanical properties are related to reduced ability of osteopenic bone to
withstand compression would not explain the results of Walsh et al. 210 who tested
fractures to failure in tension and still found differences. Additionally, while bending
creates compressive forces, the common mechanism of beam failure in bending is firstly
through failure on the tension side. Tension is primarily resisted by collagen and
collagen production is certainly influenced by the presence of oestrogen 236. Whether the
absence of oestrogen results in poorer collagen production is not clear and would benefit
from further investigation.
The effect of ovariectomy on callus size is controversial. This study showed no
difference in callus size between control and ovariectomy animals at either time point.
Some investigators have reported similar findings 210-214. Others have seen a decrease in
91191"? 9 i -3
callus size in ovariectomy models " and Cao et al. reported an increase in callus
size in their ovariectomy model six weeks following fracture compared with control.
This study did show histological evidence of reduced callus maturity with higher levels
of immature bone and porosity compared with control. Taken together these findings
raise the interesting possibility of an initial delay in callus formation in osteopenia with a
subsequent increase in size to exceed that of control later in fracture healing. This may
be related to the poorer intrinsic mechanical properties of the osteopenic callus during
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the early phase in healing leading to continued mechanical stimulus for callus formation.
The increased callus size would then appear to compensate for mechanical deficiencies
• • •• 910 91 -i
by increasing the moment of inertia. Work by Walsh et al. and Cao et al. supports
this hypothesis and shows that mechanical differences between osteopenic and normal
bone have been abolished by six weeks post fracture.
Overall a picture of decreased callus maturity emerges in the osteopenic model. As
mentioned earlier this appears to reflect a failure of the normal processes of tissue
formation with evidence suggesting that the effect is independent of the better known
_ • • 7-37
pro-resorptive effect of osteopenia. Flick et al. showed that complete blockade of
RANK, a key activator of osteoclasts, had no effect on callus formation or early fracture
• 7-37 . .
healing . This means that attempts to influence fracture healing in osteopenia with
anti-osteoclast cytokines such as osteoprotegerin would be unsuccessful. In other words,
more benefit is likely to be derived from efforts to promote anabolic processes in early
osteopenic fracture repair and this is borne out by the exciting results reported with
7*> o
recombinant PTH (teriparatide) when it is given in the early stages after fracture
Komatsubara et al239 showed that teriparatide promoted the early replacement ofwoven
bone to lamellar bone which would appear to address one of the main deficiencies seen
in the maturation of the calluses in this study. The absence of any effect ofRANK
blockade on fracture healing would also makes it unlikely that the deficient bone healing
in osteopenia is due to the upregulation ofRANK seen in the anoestrous state. This
hypothesis is supported by the findings of Ulrich-Vinther et al. 240 who found that gene
therapy with adeno-associated virus transformed to induce production of osteoprotegerin
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actually hindered fracture repair in a rat model. A reduction in the number of osteoclasts
was seen but it was associated with a reduction in the production of woven bone and a
reduced elastic modulus of the callus. This work implies that functioning osteoclasts are
required for normal maturation of the callus.
The growth factors investigated in this study did not appear to have a clear role in the
differential behaviour of the osteopenic callus versus control. Differences in osteoblast
or chondrocyte proliferation were not detected at either time point studied. An important
role for these factors cannot be excluded by this work and it can only be stated that no
difference was seen at the time points studied. Given the evidence for early callus
differences, the study of the very early stages of fracture healing might prove fruitful. In
particular, the early expression of growth factors and angiogenesis would be of interest.
Links between vascular endothelial growth factor (VEGF), oestrogen and bone mineral
density have been established 241 242 and as angiogenesis is integral to early fracture
healing, this area merits further work. There is, of course, a vast array of growth factors
now identified and in some way implicated in the process of fracture repair but in
addition to vegf, IL1 and 6 and TGF-fi are likely to be important. It was impossible to
study all of the potentially relevant factors in this study and those studied were chosen




4.4 The influence of simvastatin on fracture healing
The effect of statins on bone mineral density remains controversial. Their inhibitory
effect on protein prenylation should result in an anti-osteoclastic action as this is also
one of the mechanisms of action of the anti-resorptive nitrogen containing
bisphosphonates. Mundy et al. 63 report of a bone formation effect via BMP-2 promotion
together with the anti-resorptive effect invited investigation of the role of statin
1
supplementation in fracture healing. Other than this study, only Skoglund et al has
conducted a study on statin supplementation in fracture healing using a murine model
with normal bone mineral density. They showed a dramatic and apparently beneficial
effect on fracture healing using a very high dose of simvastatin. Unfortunately the dose
used would not be applicable in human practice due to toxicity but their findings were
nevertheless encouraging.
In this study, the dose of simvastatin used was the same as that used by Mundy et al. 63
• 79 • • •
and Maritz et al. in their work reporting contradictory, but definite, effects on bone
turnover. This dose was the equivalent of 400mg per day for an adult human which
represents five times the usual dose for treatment hypercholesterolaemia but would still
be tolerable. It was hypothesised that two weeks of 20mg/kg orally administered
simvastatin during the initial stage of fracture healing would be the most likely regime to
demonstrate any effect. It is during this stage that BMP-2 production is maximal and




In the sham operated animals no effect on the mechanical features of the healing
fractures was seen at either two or four weeks post fracture in the statin group versus
placebo. There was also no apparent effect on the expression of the growth factors
investigated. The lack of any effect raised the possibility that the simvastatin was not
reaching the bone in an active form but this is contradicted by several factors. Firstly an
increase in the proportion ofwoven bone in the statin group calluses was seen at four
weeks suggesting an effect on callus maturity. Secondly, effects of simvastatin
administration were seen in the ovariectomised animals. Finally, the technique of drug
administration and the rat model were the same as those used by previous workers who
have reported drug effects. It is technically possible to assay bone for inhibition of
protein prenylation and hence confirm a skeletal effect of simvastatin administration.
This was not however, included in the method of this study as, for the above reasons, it
was not felt to be necessary.
The results from the present study therefore show that simvastatin at 20mg/kg daily for
two weeks post fracture results in an increased level of immature bone in the sham
model at four weeks post fracture but that this does not have any significant mechanical
consequence. Further, no evidence was found for altered growth factor expression at the
times studied.
It is only possible to speculate whether a different dose or timetable of administration
would have resulted in different findings. The dose of simvastatin does seem to be
critical according to the findings ofMaritz et al. 11. Their work showed that doses lower
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than 20mg/kg given for six weeks resulted in a reduction in bone density due to an
increased resorptive state. 20mg/kg increased both bone production and resorption with
no net effect on bone mineral density. The same simvastatin dose (20mg/kg) did result in
increased BMP-2 production and bone formation in the rat model of Mundy et al. 65 It is
important to note, however, that their model of the ovariectomised rat was in a skeletally
resorptive state whereas a fracture in the early stages is anabolic. It is possible that no
effect was seen on BMP-2 or other growth factor expression in the fracture callus
because it was already maximal. Skoglund et al. 183 did not investigate growth factor
expression so it remains unknown if massive doses of simvastatin promote the already
high levels of BMP-2 expression in the early stages of fracture healing. They did show,
however, that while the callus was larger in the statin group, no histological difference
existed compared with controls. If the primary mechanical effect of simvastatin is
enlargement of callus then this effect may have been masked by the relatively smaller
callus produced in the cancellous fracture model in this study. If the many differences
which confound comparison between the study of Skoglund et a/.183 and this study are
not considered it is reasonable to conclude that the dose of simvastatin is highly
important in fracture healing. A very high but potentially toxic dose leads to a larger and
stronger callus in normal bone but a lower, more therapeutically realistic dose, hinders
callus maturity. There is an obvious need to investigate the effect of statin doses between
20 and 50mg/kg, above which toxicity has been reported (see Section 2.2.2.2).
Much clearer effects of simvastatin administration were seen in the osteopenic,
ovariectomised group. Once again the fracture callus at four weeks had a higher
157
Discussion
proportion of immature bone present compared with placebo but this was also related to
a significantly smaller callus area. The smaller callus withstood less load than might be
expected but the intrinsic properties of the callus in the drug group were also impaired
relative to control. The mechanism for this deleterious action of simvastatin did not
appear to be due to a pronounced effect on BMP-2 or 6 expression. An increased level of
Smadl expression in the chondrocytes two weeks post fracture in the simvastatin group
did suggest a possible mechanism for the drug effect. The increased Smadl levels may
have reflected a promotional effect of simvastatin on chondrocyte activity which would
fit with the increased levels of immature bone produced by endochondrial ossification. A
prolongation of the endochondral phase would result in a more immature callus but does
not account for the reduced size of the callus overall. Interestingly, Fukuyama et al.243
have shown that statins inhibit osteoblast migration in vitro which may well result in
delayed osteogenesis in a situation such as in the osteopenic model where osteogenesis
is already impaired. This effect appeared to be due to statins' inhibitory effect on protein
geranylgeranylation, a down stream product of the HMGCoA pathway.
As has been noted already, callus in the osteopenic animals appeared to be more
immature than in animals with normal bone density but simvastatin at the dose given
appears to make the situation worse. If this was due to a purely anti-resorptive effect
then immature bone would remain present but a larger callus would be expected. This
was the effect shown by Cao et al. 213 on callus formation following administration of
the anti-resorptive bisphosphonate alendronate in an osteopenic rat model. The anabolic
simvastatin effect proposed by Mundy et al. 71 would also be expected to result in a
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larger callus albeit possibly of lesser maturity. It may be that while some promotion of
endochondrial ossification did occur due to simvastatin in this study, the pro-resorptive
anoestrous environment prevented formation of a larger callus. This would result in a
callus with poorer mechanical properties as seen in this situation.
Another potentially confounding factor when using the ovx model for the study of
statins is the link between the effect of statins on adipocytes and bone. It is well known,
and shown in this study, that ovariectomy results in weight gain by production of
adipose tissue. It is thought that adipose tissue and bone tissue production have an
inverse relationship with increased adiposity of bone marrow being associated with
reduced bone density 244. The link is perhaps not surprising due to the common
mesenchymal stem for both types of connective tissue. Li et al.245 reported that
lovastatin enhanced osteoblast differentiation at the cost of suppressing fat cell promoter
levels and hypothesised that the statin shunted uncommitted osteoprogenitor cells from
the adipocytic to the osteoblastic pathways. In the post ovariectomy model it is possible
that the pro-adipocytic drive is too influential to allow the dose of statin used to promote
osteogenesis.
The peptide hormone leptin appears to be integrally involved with the regulation of
adipose tissue and its link with bone density246. Leptin treatment has been shown to
increase bone formation in leptin deficient mice244. It is thought though that leptin levels
fall in the oestrogen deficient state encountered post ovariectomy or physiological
menopause 247. Although one study actually reported an increase in serum leptin levels
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at day 20 post ovariectomy in the rat 248. The role of leptin in the regulation of BMD is
further confused by some workers reporting a positive association of leptin with BMD
249 and others finding no correlation2s0. Leptin has also been shown to cause an increase
in gene expression for vegf in other tissues 251 suggesting a pro-angiogenic role. What is
clear is that leptin and, by implication adipose tissue, have an influence over bone
production and regulation which is very likely to be affected by statin treatment. From
the currently available evidence it is not possible to predict how statin therapy in the
anoestrous environment would influence serum leptin levels. This may however, provide
another explanation for the unexpected effects of statin supplementation in the ovx
model in this study and would be an exciting area for further work.
The reason for the poorer mechanical properties of the osteopenic callus compared with
control and the apparent worsening of the situation by administration of simvastatin at
the dose used is not explained by the findings of this study. This reflects the complexity
of the processes involved in fracture healing and the current lack of understanding of the
process in relation to osteopenia. The view that simvastatin promoted BMP-2 expression
and would therefore prove beneficial in fracture healing has not been supported by this
work. Fracture healing is an intricate balance of formation and resorption with the
timing of these processes critical to the integrity of the healing fracture. Attempts to




Further attempts to elicit the cause for a difference in the mechanical properties of
fracture healing in osteopenia and control are warranted. Establishing the patterns of
expression and functional role for the host of growth factors not investigated in this
study might lead to the discovery of an exploitable difference between these groups. Of
particular interest are the pro-osteoclastic cytokines interleukin 1 and 6 and tumour
necrosis factor and the angiogenic VEGF. Investigation of the initial stages of fracture
repair may reveal important differences in the way that osteopenic bone responds to
injury and initiates healing. Such information would be beneficial in making the use of
evolving techniques such as gene therapy to enhance fracture healing.
Parathyroid hormone is emerging as a promising agent for the treatment of osteoporosis
and enhancement of fracture healing. Investigation of its role in osteoporotic fracture
healing is certainly merited and has already been undertaken by some investigators. PTH
has the potential to fulfil the much needed role of a truly anabolic agent in fracture
healing and osteoporosis. However, concerns about the oncogenic potential ofPTH must
be conclusively addressed for it to have a major future role in this area.
The future for statins in the field of fracture healing is not clear. Very little work has
been done on their role in fracture healing with the only other study reporting
contradictory results. As discussed above there are many potential reasons why
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contradictory results are being reported in this field. This simply reflects the lack of
understanding of the fracture healing process in osteopenic bone and the complexities of
the links between different systems and metabolic pathways such as those between
adipose tissue and bone. More work is required on the role of leptin in osteoporosis and
its link with statins. This study has provided enough evidence to show that statins do
influence fracture repair and there is therefore more to be gained by persevering with the
study of statins in this field. In particular the timing, delivery and perhaps most
importantly, the biologically available dose, seem likely to be critical factors. The
introduction of newer more lipophilic statins should not be ignored as these are likely to




This study has shown that ovariectomy resulted in poorer mechanical properties of the
healing tibial fracture at four weeks post fracture compared with control. This provides
supportive evidence for the hypothesis that the anoestrous environment is deleterious to
the early stages of fracture healing. The callus in the osteopenic model appeared to have
a lower density of bone as early as four weeks post fracture representing either an
impairment of bone formation or inappropriately accelerated bone resorption.
Additionally, the presence of higher levels of undifferentiated tissue in these fractures
suggested a general impairment of callus maturation. These differences were not
associated with any changes in the expression of the growth factors studied or in the
replication of key cell populations.
Contrary to previous work the dose and method of delivery of simvastatin in this study
had no apparent effect on the mechanical properties of the healing tibial fractures in
normal bone. This dose of simvastatin had no effect on the expression of BMP-2 or
related factors in the fracture calluses from normal bone at the time points studied.
Simvastatin did have a deleterious effect on the properties of healing fractures in the
osteopenic model with a reduction in callus size and maturity and the ability of the
healing fractures to withstand load. The reduced levels of smad-1 in the chondrocytes
and the retardation of bone maturation in this group suggests simvastatin has an
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Al.l Specimen Automated Processing Protocol
Specimens processed in Vacuum Infiltrated Processor (VIP, Tissue Tech VIP, E300
series, Miles Inc)
Alcohol 50%, 2 hours at 35°C
Alcohol 80%, 1 hour at 35°C
Alcohol 95%, 1 hour at 35°C
Alcohol 100%, 1 hour at 35°C
Alcohol 100%, 1 hour at 35°C
Alcohol 100%, 2 hours at 35°C
Xylene 100%, 3 changes of 1 hour each
Paraffin, 4 changes of 1 hour each at 60°C
Specimens moulded in paraffin blocks
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1) Dewax and rehydrate sections through graded alcohols to water
2) Immerse in haematoxylin for 3 minutes
3) Wash sections through 3 changes of tap water 1 minute each
4) Immerse in Scott's tap water for 30 seconds to blue
5) Immerse in eosin for 30 seconds
6) Wash sections in tap water for 1 minute
7) Dehydrate sections through graded alcohols to absolute alcohol (2 changes)
8) Sections through 3 changes of xylene and mount




A1.3 Immunohistochemistry with the Avidin-Biotin-Complex (ABC) method
Method
1) Dewax and rehydrate sections through graded alcohols to distilled water
2) Block endogenous peroxidase by immersion of slides in 3% FEO? for lOmins
3) Wash in PBS
4) Perform desired antigen retrieval
5) Wash in PBS and mount slides in sequenza
6) Add 1 OOul avidin block for 10 minutes
7) Wash PBS
8) Add lOOul biotin block for 10 minutes
9) Wash PBS
10) Add 1 OOul Dako protein block for 10 minutes
11) Add 125ul of primary antibody at desired concentration and incubate for desired
period
12)Wash PBS
13) Add 125ul of biotinylated secondary antibody at concentration of 1:400 and
incubate for 30 minutes at room temperature
14)Wash PBS
15) Add lOOul RTU ABC Vecastain and incubate for 30 minutes at room
temperature.
16) Wash PBS
17) Add 125ul ofDAB + substrate chromogen and incubate for 5 minutes at room
temperature
18) Wash in PBS
19) Transfer to staining rack and counterstain in haematoxylin
20) Dehydrate slides through graded alcohols to absolute alcohol and mount slides
from xylene
Positively stained structures appear brown when viewed under direct light microscopy
Materials
Hydrogen peroxide H2O2 (H1009)
Avidin / Biotin Block (Sp2001)
Dako Protein Block (X0909)
Desired primary antibody
Biotinylated rabbit-anti-goat secondary a/b(E0466)
RTU ABC Vecastain Kit (Pk-7100)









_A1.4 Trypsin Antigen Retrieval
Materials
Trypsin (porcine type 2, pancreas) T 7409




Dissolve 0.5g of trypsin and 0.5g CaCl2 in 500 ml of distilled water
Correct pH to 7.7 with TRIS at room temperature
Method
Preheat solution to 37°C in water bath
Immerse dewaxed, hydrated slides in solution for desired length of time. Remove slides
and rinse on PBS. Proceed with assay.
A1.5 EDTA Antigen Retrieval
Preparation
Prepare ImM solution ofEDTA in 11 of distilled water. Add 0.1% by volume Tween-20
and correct pH to 8 with NaOH.
Method
Preheat solution to 65°C on a stirrer. Immerse dewaxed and hydrated slides in solution
and leave overnight. Place lid on beaker to prevent evaporation and drying out of slides.
Next morning remove from hotplate and cool to room temp. Rinse slides in tap water
and proceed with assay.
Materials
Ethylene Diamide Tetra Acetic Acid EDTA(CioHi6N2Og)
Sodium Hydroxide (NaOH)






A1.6 Immunohistochemistry with ARK - (Animal Research Kit) DAKO
The following must be calculated prior to beginning the assay:
a) Working volume = no. of slides x lOOul
b) Volume of concentrated primary antibody = (a) x final dilution
c) Volume of biotinylated reagent = primary stock conc. / 100 x (b)
d) Volume of blocking agent = (a) / 25
e) Volume of diluent = (a)- (b + c + d)
Preparation of biotinylated primary antibody
Add primary antibody (b) to biotinylated reagent (c) and diluent (e). Incubate for 15
minutes at room temperature. Add blocking solution (d) and incubate for at least 5
minutes.
Biotinylated reagent - biotinylated anti-mouse IgG containing TRIS-HCL, protein and
sodium azide
Blocking agent - normal mouse serum in TRIS-HCL buffer, protein and sodium azide
Diluent - ChemMate Antibody Diluent, (Dako Cytomation) containing Tris buffer,
15mmol sodium azide and protein at pH 7.2
Method
1) Sections prepared and antigen retrieval performed as described in relevant
method section
2) Sections washed in PBS and load into sequenza (Shandon) ensuring absence of
air bubbles and good seal with cover slip
3) lOOul of peroxidase block (0.03% hydrogen peroxide containing sodium azide)
added to each slide for 5 minutes at room temperature.
4) Slides washed with PBS
5) lOOul of biotinylated primary antibody added for desired time
6) Slides washed with PBS
7) 1 OOul of streptavidin-peroxidase added for 15 minutes at room temperature
8) Slides washed in PBS
9) lOOul of 3,3-diaminobenzidine (DAB) + Substrate chromogen added for 5
minutes at room temp.
10) Slides washed with distilled water
11) Slides transferred to staining rack and immersed in haematoxylin for 30 seconds
12)Wash in tap water
13) Immerse in Scott's Tap Water for 30 seconds
14) Wash in tap water
15) Dehydrate through alcohol 64 OP, 74 OP, absolute, 1 minute each
16) Mount from xylene
Positive staining is represented by brown coloured precipitate at the antigen site.
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Intra / interobserver error for immunohistochemical analysis
As the data were ordinal, a linear weighted Kappa was calculated using Vasser Stats










































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix3.6Uterinew ights(g)forallsp cimen X-denotesexcludedspecim n
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Mean load at yield
Mean Load at failure
112 N (95% CI 111.4, 112.6)
108N (95% CI 101.5, 114.5)
Linear regression analysis of data to yield
point"
Correlation coefficient (r) 0.9241
ANOVA PO.OOl
Slope 0.1219 (95% CI 0.1526, 0.1653)
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